RAPID THERMAL CYCLE PROCESSING METHODS AND APPARATUS

Abstract: A system and method for processing a lipid membrane bound structure, the method comprising the steps of providing the structure to be processed in a liquid medium; and heating the liquid medium containing the structure at a rate and through a range sufficient to cause a discrete phase transition in at least one of the membranes, such that the membranes fuse. The method may be used to fuse the structure with another structure, or to reduce the integrity of the structure. The apparatus atomizes a medium containing the structure into small droplets and subjects them to an environment containing steam vapor while moving at high velocity, to rapidly increase the droplet temperature to the steam temperature by release of the latent heat of vaporization.

Description: RAPID THERMAL CYCLE PROCESSING METHODS AND APPARATUS FIELD OF THE INVENTION The present invention relates to the field of thermal processing of biological matter to alter or kill the cells. More particularly, a rapid rise in temperature is employed in a manner which avoids denaturatton of proteins while altering membrane properties. BACKGROUND OF THE INVENTION It is well known that biological cells may be killed in a manner of Pasteurization, in which the time temperature product of a process is sufficient to denature cell proteins necessary for vitality. Other cell killing mechanisms are known which involve physical process, such as shear forces, ultrasonic cavitation, alteration in membrane properties through the insertion of pores, and the like. A number of methods are known for reducing bacterial activity in liquids. Traditionally, a so-called "Pasteurization" process is employed, which operates by the principles of thermal denaturatton of proteins to inactivate bacteria. Thus, the liquid is raised to a particular temperature for a proscribed duration, to effect a statistical reduction in die number of, or even elimination of all viable bacteria. In an effort to reduce a duration of the process, high temperatures may be employed, which raise the temperature of the fluid to, e.g., 150°C for 2-4 seconds under pressure, followed by a flashing (rapid boiling) to lower the temperature, thus limiting d e duration of die treatment. Such systems thus require a very high temperature, and may alter a taste of a potable liquid or food product, such as is the case with milk. Depending on how d e heat is applied, precipitation of proteins in the product or other physical changes may occur. In addition, the presence of oxygen duπng treatment may cause accelerated oxidation. The heat treatment processes for fluid food products (e.g., milk) are applied for destroying disease-causing microorganisms, as well as inactivating microorganisms which may spoil the food. In many known processes, the bacterial reduction is a preservation technique which extends d e shelf life, but sterilization is not achieved. Some of these pasteurization techniques involving heat treatment of food products, for instance, milk, are disclosed in USSR Pat. No. N 463,250 M KI A 23c 3/02 and N 427532 M KI 28 9/00 A 23c 3/02. The most widely used Pasteurized technique involves subjecting food products to heat treatment as high as 65-75°C and exposing same to tins temperature for a period of time of 30 minutes. This is the so-called long-term heat treatment The second technique involves subjecting food products to heat treatment at a temperature of 70-75°C and exposing same to this temperature for a period of time of 2-4 minutes The third technique involves subject food products to short term heat treatment at a temperature of 95°C and exposing same to this temperature for 30 seconds. The fourth technique includes ultra high temperature heat treatment. It involves subjecting food products to a temperature of 110-140°C and exposing same to this temperature for a period of time of 2-3 seconds. These treatment are thus based on a d ermostability time-temperature relationship of microorganisms. Thermostable life-time is defined as a life-time of microorganisms at a given temperature. The higher the temperature, the shorter the thermostable period. An effective Pasteurization treatment thus subjects food products to heat treatment at a certain temperature for a period of time which is longer than the thermostable period. These pπor art techmques are generally directed toward the thermal denaturaαon of essential cell elements, they effectively cook the treated medium, including any biological organisms therewithin. Thus, proteins lose their tertiary structure, cells are killed, and heat labile components are adversely affected. Sediments may also be formed, which may necessitate regular cleaning of the system, especially any higher temperature portions, such as heat exchange surfaces. Some of these drawbacks can be avoided by using the direct heat treatment, which heats the product by way of direct contact of the product subjected to Pasteurization with the heating medium, for instance, steam, rather than through a heat transferring surface of heat exchange equipment. This method eliminates release of the milk "stone" in die heating zone and lessens its appearance on other surfaces of the equipment. These known mediods transfer the product into die Pasteurizer, and inject steam made from potable water to a desired temperature, for a desired period. The product is cooled and excess water from condensed steam eliminated. This technique allows a relatively quick heat treatment of the product, and has been found of particular use in ultra high temperature heat treatments The technique avoids exposure to temperatures higher than a desired final temperature, and thus may limit sedimentation, which may appear, for example, as milk "stone" in a Pasteurization process. Where direct steam contact is used, it dilutes die medium, for example up to 30% of the product mass, with an ultra- high temperature Pasteurization techmque, which subsequendy is often removed. These known methods of Pasteurization strive to maintain laminar flow of milk duπng the process, and thus do not atomize the milk. As a result, these systems fail to raise the temperature of the bulk of the milk at a rapid rate, and rather gradually raise the bulk temperature to the Pasteurization temperature, at which the milk is maintained for the desired penod. Of course, a small surface layer may expeπence rapid temperature πses. Zhang, et al., "Engineering Aspects of Pulsed Electπc Field Pasteurization", Elsevier Publishing Co. (1994) 0260-8774(94)00030-1, pp. 261-281, incorporated herein by reference, relates to Pulsed Electnc Field Pasteurization, a non-thermal Pasteurization method. This method (as well as other biological treatment methods) may be combined wid other methods, to enhance efficacy of the composite process, while avoiding the limitations of an excess exposure to any one process. RU 2,052,967 (Cl) relates to a rapid temperature πse bactencidal treatment method, similar to the present method, but intended to non-selecttvely kill organisms. Abrams et al, US 3,041,958 relates to a steam processing temperature control apparatus. Wakeman, US 3,156,176 relates to a steam Pasteurization system. Stewart, US 3,182,975 relates to a steam injection heater, which employs impeller blades to mix steam and milk for rapid heating. Engel, US 3,450,022 relates to a steam rnfuser for high temperature steam treatment of liquids. Nelson, US 3,451,327 relates to a steam injector for a milk sterilizer. This device is intended to bring the milk to a high temperature, and thus allows thermal communication between d e steam and milk pnor to venting. De Stoutz, US 3,934,042 relates to a system for treating beverages, including milk, beer, wine and fruit juices, for sterilization or Pasteurization. The liquid is held at elevated temperatures for extended periods. Janivtchik, US 4,160,002 relates to steam injectors for Pasteurizing milk using pressurized steam. Wakeman, US 4,161,909 relates to an ultrahigh temperature heating system for heating, e.g., milk. The milk falls in a curtain configuration in a steam chamber. The milk is held at a high temperature after heating Nahra et al. US 4,591,463, and Nahra et al. Re. 32,695, incorporated herein by reference, relate to a milk ultra Pasteurization apparams in which sheets of milk fall within a steam filled chamber for ultra high temperature Pasteurization. Bronnert, US 4,787,304 and 4,776,268 relate to an infusion heating apparatus for sterilizing liquid food products, having a porous steam dispensing cylinder or diffuser located along a central axis of a treatment vessel. Sanchez Rodriguez, US 5,209,157 relates to a diary preparation system which involves an ultrahigh temperature treatment step. It is also well known to fuse cell membranes through the use of so-called fusion proteins, chemical agents, photomc effects, and possibly by application of heat. Cell fusion has been used to form hybrid cells or hybndomas, to insert cell surface proteins or to alter cell cytoplasmic chemistry The Rapid Thermal Cycle Processing (RTCP) Technology is relatively unexplored as a mechamsm for treating of cells It is known, however, that RTCP is capable of killing bacteπa at temperatures below those which tend to denature bactena. The RTCP process, also known as MilliSecond Pasteurization ("MSP") involves the heating of fluid droplets with saturated steam, at a high rate of increase, for example, over a thousand degrees per second, to a desired temperature, typically under conditions which do not denature (a chemical process which alters structure) proteins. When appropriately processed, fluids may be sterilized, widiout otherwise changing macromolecular structures. RTCP technology has been proposed for the "Pasteurization" of milk, to kill bacteπa and spores in d e milk. A microwave Pasteurization and Sterilization process is disclosed in Stanley E. Charm et al. (Charm Sciences, Inc., Maiden MA), U.S. Patent Nos. 4,839,142, 4,975,246, and 5,389,335, expressly incorporated herein by reference. These patents disclose a process which is said to sterilize food products without substantial protein denaturation by rapid heating (25 - 8000° C per second) and cooling of d e treated product within a short time. SUMMARY OF THE INVENTION The present invention provides a rapid thermal cycle processing system which provides a high rate of temperature change, which primarily is directed to formed cell components, such as membranes. In particular, the outer cell membrane is a focus of the action. While the mechamsm of action is subject to speculation, it is believed diat a primary effect of the rapid temperature transition is to generate a shock wave. In addition, die rapid rate of temperature nse is fast enough that diffusion of lipids in the membrane is incomplete, so mat domains of membrane remain with differing characteπstics, such as glass transition temperature. Thus, die temperature nse may have a different qualitative effect on certain regions as compared to others. While RTCP is capable of killing cells, likely by disrupting membranes, the RTCP process, need not always be applied under such conditions as kill the cells This readilv apparent from studies which were performed in which a surviving fraction of bacteria remained. In some tests, diese bacteria formed aberrant colomes when cultured. Thus, by subjecting die cells to RTCP under mild conditions, alterations may occur which are non-lethal. This observation has presented many significant and exciting opportunities. These opportunities include cell membrane fusion, presentation of cellular antigens for immune response, induction of specific cell responses, and cellular "reprogramming". RTCP also has potential industrial applications in the biotechnology industry for sterilization, cell lysis, cell manipulation and cell fusion, and in die chemical industry for rapid and uniform heating, selective melting, reaction initiation and encapsulation or trapping of pa culates. The present invention seeks to alter cell charactenstics by a thermal shock process, which may be used, for example, to inactivate or kill bactena, alter cell surface chemistry or antigenicity, disrupt membranes, activate cell functions or responses, disaggregate cells, as a pretreatment before cell fusion or infection, activate or change the function of a cellular parasite (bacteria, mycoplasma, virus, pπon, etc.), affect mitochondnal functioning or the functioning of other organelles. On an organism level, the present invention may be used to treat bacterial infections, such as osteomyelitis, viral infections such as AIDS, human or animal Herpes viruses (including HHV-5 and EBV, as well as CMV, HSV-1, HSV-2, VZV, HHV-8, and the like), treat cancer, sarcoma, mesothehoma, teratoma or other mahgnancv or neoplasm, treat skin conditions, such as psoriasis, treat inflammation, treat fungal diseases, blood borne diseases, leukemias and die like. The present invention may also have utility in die treatment of syndromes, which may be multifactoπal in oπgin and involve an immunological component or defect. Therefore, the present invention may also find utility in die treatment of chrome fatigue syndrome (CFS), for example bv applying immune stimulation therapy through treatment of blood or blood components. The broad utility of the present invention comes from its ability to carefully control a stress apphed to a cell. This stress may, of course, kill the cell or selectively kill a subpopulatton of cells, but more importandy, it is beheved that the present invention may be apphed to cells to have a measurable non-transient effect which does not immediately result in cell dead In this manner, the present method provides a new manipulation modality for cells. In contrast to known cellular thermal lnactivation methods, die major aspects of the present invention do not rely on thermal denaturatton of cellular proteins and enzymes, but rather on a rapid temperature nse which irreversibly changes the cell, at temperatures and energy levels below those required by traditional Pasteurization processes. In particular, according to one embodiment of the system and mediod according to die present invention, a product is treated such diat die temperature of a medium in which all or a portion of the cells exist nses at such a rapid rate that normal accommodation mechanisms, which might allow the cell to avoid permanent effect from a slower temperature nse rate treatment, are unavailable or ineffective. Thus, it is an aspect of die present invention to alter cell functioning based on a rate of temperature change during treatment, rather than based on a time-temperature product function or a maximum temperature. The present invention is dius beheved to operate by a physical principle different than diermal denaturation, the pπnciple behind Pasteurization. Rather than a thermal denaturation of the proteins, as well as proteins which may be in the extracellular medium, one aspect of the present invention operates by thermal shock, which is beheved to disrupt or alter membrane structures or membrane components of cells. Typical media for treatment include milk, egg white, blood plasma, cell culture medium, fermentation broth, fruit juices, and die like. Thus, rather than a high temperature, per se, the present invention requires a high rate of temperature nse. The resulting maximum temperature may be limited to temperatures which do not denature vanous proteins, e.g., a maximum temperature of 0-75°C. It is clear, therefore, that the maximum temperature may remain sub-physiological, or nse to relatively high levels. For food processing, the maximum temperatures will often be on the higher end of the scale, in die 40-75°C range, while in medical or pharmaceutical process, the maximum temperatures will often be in die middle of the range, e.g., 15-55°C. Sterilization of non-heat labile media may occur at high temperatures, e.g., greater than 110°C, for example where the media is contaminated by thermotrophic organisms. One uieory of operation of the present invention relates to the glass transition temperature of membrane structures. Cellular membranes are generally formed of phosphohpid bilayers with proteins, hpoproteins and glycoproteins inserted on the inside, outside, or protruding through the membrane. The membrane, especially the fatty acid chains of the phosphohpids, are physiologically maintained in a fluid condition, and d us kpids and proteins are motile across the surface of the membrane. For example, under comparable circumstances, a hpid molecule may travel at a rate of about 2 microns per second, with proteins traveling at a rate of several microns per minute, in die plane of the membrane Membrane components, though mobile in die plane of the membrane, are generally slow to switch or invert between die outer and inner surface. For example, transverse diffusion rate of phosphohpids is about 10 9 the rate of lateral diffusion, for a typical 5θA distance (the thickness of a phosphohpid bilayer membrane) The viscosity of a cell membrane typically is about 100 times that of water. On the odier hand, the membrane structures of living cells have some long-term ordering of molecules, especially the structures on the surface of the membrane (as opposed to die pid phase in die middle of die membrane), and therefore are in this sense somewhat crystalline. Thus, the phrase "liquid crystal" is apt for the composite structure. Among other functions, die controlled membrane fluidity is beheved to be necessary for vanous mediated transport systems which involve die movement of earners within or through the membrane. The membrane proteins also have, in their natural state, a separation of charged and uncharged portions, allowing stable insertion of hpophihc portions of the proteins into die membrane structure, with hydrophihc portions protruding extracellu rly or lntracellularly from the membrane, into die cytoplasm or extracellular fluid. Intracellular membranes may also have asymmetry Since die phosphohpids are essentially undistinguished, die long term (ι.e., over distances of tens of Angstroms) ordering of the membrane along its surface is related to arrangements of the protein components and die polar end-groups of the phosphohpids. Some of the proteins or protein structures which extend dirough the membrane provide channels which allow ions, such as sodium, potassium and chlonde to readily cross, or to be selectively controlled or pumped. The size of the channel allows selectivity between differing ions, e.g., sodium and potassium. The tertiary configuration of the proteins (the diree dimensional structure of a single protein molecule), and quaternary configuration of peptide structures (the spatial interaction of separate molecules) are thus cnttcal for proper protein insertion in the membrane, and protein functioning. Thus, the membrane is ordered, and dus ordering relates to its function. A disruptton of the ordering affects the cell function, and may destroy die cell, or have a lesser damaging, distinct or selective effect The membrane fluidity may be controlled by fatty acid composition. For example, bactena use this mechamsm. The fatty acyl chains of hpid molecules may exist in an ordered, crystal-hke state or in a relatively disordered fluid state. The transition from the ordered to disordered state occurs when the temperature is raised above a "melting" temperature, or more properly, a glass transition temperature. In the case of fatty acyl chains within the membrane, the physiological state is fluidic. Of course, the membrane structure may have a number of different glass transition temperatures, for the vanous components and dieir respective energetically favorable ordenngs which may exist. This glass transition temperature depends on a number of factors, including die lengdi of the fatty acyl side chain and dieir degree of unsaturation Unsaturation (with d e naturally occurring cis-onented carbon-carbon bonds) causes "kinks" in d e side chains, and increases bond rotation on either side of the unsaturation, both of which impair orderly packing, thus reducing crystallinity and increasing die glass transition temperature. Long fatty acyl chains interact more strongly, stabilizing the structure, and in mcrease in their proportion leads to a decrease in glass transition temperature. Higher orgamsms have cholesterol in their membranes, which increases membrane fluidity. The cholesterol content may be controlled to control fluidity. It is known that in E. coll, the ratio of saturated to unsaturated fatty acyl chains in the cell membrane decreases from 1.6 to 1.0 as the temperature decreases from 42°C to 27°C. This decrease in d e proportion of saturated residues is beheved to prevent the membrane from becoming too ngid at lower temperatures. Higher species, including mammals, regulate cell membrane fluidity d rough cholesterol content, although tins mechanism is beheved to be absent in bacteπa. It is beheved diat diese membrane-composition accommodation mechanisms are comparatively slow. It is also beheved diat orgamsms, such as bactena, maintain dieir cell membranes a number of degrees below an important glass transition temperature of the membrane, d us assuring a balance between membrane fluidity and crystal ne-hke ordering. This crystalline state also implies a non-hnear response of the membrane to temperature variations around die glass transition temperature. Cellular mechanisms are beheved to be present which assure that, through commonly encountered temperature variations, irreversible cellular damage does not occur. Some of these mechanisms are active or controlled, and dius have a latency Some of these temperature changes mav also tngger physiological cellular responses, such as so-called temperature shock protems. Some of these mechamsms are physical and passive, and dius occur relativeh rapidly These include stretching, membrane shape changes, and die like. According to diis theory, the system and mediod according to die present invention seek to take advantage of these delayed responses in die accommodation mechamsms to temperature increases, by increasing the temperature, through this glass transition temperature, at such a rate that d e cellular mechamsms do not have a chance to effectively respond, dius allowing irreversible damage to die bactena, presumably through a disruption of the higher levels of organization, without necessarily affecting die lower organizational levels of structure. Thus, the temperature of the bacteria need not be raised to a temperature sufficient to thermally denature the tertiary structure of proteins. Another theory for the observed bacteπcidal effect, and indeed die sterilizing effect beheved to exist, is that, though the temperature of the cells is raised, it is not raised sufficiendy to completely fluidize die membranes, leaving diem comparatively stiff, bnttle or non-comphant The thermal shock according to d e present invention also produces a mechanical stress, which may damage or affect the membrane. This damage may result in lysis, or a less severe mechanical disruption, which may later result in cell deadi or other response. This mechamcal stress may also activate cellular processes or otherwise influence cell functioning. This effect is essentially opposite to diat seen in high temperature Pasteurization (HTP), wherein the sustained higher temperatures tend to hquefy die membrane; although these HTP processes are specifically intended to diermally denature proteins to inactivate cells. High temperature change rates are needed m order to prevent the relaxation of structural changes in a cell, e.g , the cellular membrane, which occur over approximately 10-100 mS. With temperature nse rates in excess of this rate, an effect occurs, which may, for example, disrupt or inactivate bactena or cells or have other effects. The induced diermal shock thus produces a number of effects on die cell. First, the cell rapidly expands due to die increase in temperature. Second, d e cellular membranes may expeπence a configurational change either as a primary effect or secondarily due to a phase, volume or shape change of cellular components. Third, while thermal denaturatton generally is directed to essentially irreversible changes in the tertiary protein structures of cnttcal proteins and enzymes, thermal shock may effectively reduce quaternary organization to control or alter the cell. Microtubule structures and nucleic acid conformations may also be affected. According to die present invention, one method for inducing diis controlled vet rapid temperature nse is by treating medium containing die cells, generally in relatively small droplets to provide a large surface area to volume ratio and small thermal inertia, held at a starting temperature, with an excess of steam at the desired final temperature. The interaction between the droplets and steam is rapid, equilibrating widiin milliseconds at die final temperature, with only a small amount of dilution due to die high latent heat of vaporization of steam. Generally, in order to reduce a rate-limiting boundary layer, the droplets are degassed prior to treatment. The water derived from condensed steam chemically dilutes d e droplets, rather than mechanically diluting diem. In d e case of milk, this means mat d e water is associated wid the milk proteins, and the treatment does not substantially adversely affect the flavor of the milk. This excess water may also be removed. In die case of biological media, the dilution is relatively small, depending on temperature rise, and dierefore is unlikely to induce a substantial hypotonic shock. However, to the extent diat diis hypotonic shock does induce a response, that response forms a part of the present invention. Alternately, other controlled addition of energy to the cell-containing medium or tissue may be used. Thus, a microwave device may be used, which heats the medium through molecular excitation. The power of the microwave is controlled so that the medium is heated to a desired temperature over a desired period. The energy is apphed rapidly, in order to obtain the desired temperature rise rate, e.g., in excess of 1000°C per second, over a short period. The treatment may also be apphed to tissues, since atomization is unnecessary. The use of rapidly apphed microwave radiation also means d at thermal diffusion or blood perfusion become comparatively insignificant factors in the treatment. The volume to be treated may be physically measured, estimated, or empirically determined by a "test" treatment which applies a relatively small amount of energy and determines the temperature rise in response. In any case, it is important to assure uniformity of treatment of bulk tissues, in order to prevent spatial variations in treatment. However, where the goal is not treatment of all cells within the organ or tissue, for example and organ such as lung, liver or brain, or a tissue such as a solid tumor, then the treatment may be directed toward a portion of the tissue, widi care taken not to over-treat any essential tissues. Thus, non-uniform or non-uniform fields of microwaves or infrared radiation (coherent or incoherent, monochromatic or broadband) may be employed to heat cells or tissues. In general, visible or ionizing radiation and acoustic waves are not generally preferred energy sources because, in order to raise the temperature by the desired amount, other effects will likely be produced in the tissues. However, where these od er effects are desired or complementary, they may be employed. For example, ionizing radiation may have a different mechanism for killing or altering cells, where this effect is desired. A composite treatment may also be fashioned, in which a core tissue is destroyed, while a penpheral shell is partially treated. It is known diat one mechamsm by which neoplastic cells escape normal immunological surveillance is by hiding anttgenic factors from the cell surface, or even not producing certain anttgenic markers. It is beheved that this aspect of the present invention will overcome these mechamsms are disrupt or alter membranes so that anαgenic markers or elements are accessible. In this case, cell deadi is not necessary for efficacy, as the mere presentation of unique or characteπstic antigens may be sufficient to spur an lmmunologic response which results in an effective treatment. Blood presents certain interesting properties material to its application for treatment according to die present invention. First, it may be transferred to an exttacorporeal reactor Second, blood components may be separated in real time, in a plasmapheresis process, and individual blood components (erythrocytes, leukocytes, platelets, plasma, etc.) treated separately Third, it is a liquid which maybe separated into small droplets. Thus, blood treatment may be effected through the steam chamber, using treatment parameters which do not coagulate or denature blood proteins. Generally, a useful blood treatment does not attempt to kill all blood cells, or one would simply extravasate without reinfiision, or separate undesired cell components and not reinfiise undesired components. Therefore, often a goal of therapy is either selective treatment of a subpopulation of die cells, or a non-lethal treatment apphed non-selecttvely to all or some of the cells present. In order to effect a non-lethal treatment, the temperature nse rate is controlled, and/or die temperature nse and/or maximum temperature is controlled. Blood treatments may be effective, for example, to treat chrome fatigue syndrome (CFS), acquired immune deficiency syndrome (AIDS), malana, babesiosis, other viral, bacterial, fungal or parasitic diseases, leukemias or other blood-borne neoplasms, blood dysplasias and dyscrasias, immune disorders and syndromes. Bactenal-associated autoimmune mediated disorders, such as tiiose related to spirochetes (syphilis, Lyme disease), as well as other autoimmune related diseases, such as rheumatoid arthntis and lupus, may also be subject to tteatment accordmg to the present invention. This later treatment may be apphed, for example, to lymphocytes, which mediate immune responses. In some syndromes, viruses play a primary or ancillary role. Many types of viruses have a hpid coat, which is, for example, denved from the cell membrane of a host cell before budding or lysis, generally widi viral-specific proteins or glycoproteins It is charactensttc of chrome viral infections diat die viruses avoid vigorous immunological response by not presenting anαgemc proteins, or by mimicking host protems. On the odier hand, some chrome viral infections produce an autoimmune response which does not particularly target or eliminate viral infected cells. In either case, the temperature shock method accordmg to die present invention allows relatively mild reconfiguration of membranes, allowing normally unavailable antigemc markers of membrane protems or lntracellular protems to be presented to die host immune system. For example, a cell membrane inversion may take place, presenting internal antigens. Thus, any disease which is characterized by deficient or misdirected host immunological response is a candidate for treatment accordmg to die present mvention. Accordmgly, cells which are accessible through the blood, skin or in particular organs may be targeted wid the temperature shock treatment. It is also noted diat temperature shock may be used to redirect the activities of a cell. For example, circulating immune cells may be refractory or hyperstimulated. A treatment accordmg to die present mvention may be used to "resynchronize" or reset cells to obtain a normal response. Thus, the present mvention need not be directed to die treatment or destruction of abnormal cells, but rather to the use of temperature shock for a vanety of purposes. Since die treatment of an individual patient does not necessarily require high throughput, other energy sources may be used, besides steam and microwaves, including general infrared, laser, maser, and chemical sources. Therefore, for example, a stream of blood, or blood component(s), may be subjected to a controlled low power Cθ2 laser or microwave treatment to effect the temperature shock treatment. Further, usmg cell separatton techmques, such as those developed by Coulter Electronics, Hialeah, FL, individual blood cells may be separated and individually treated, based on an identification of type, and dien, for example, reinfused mto the host. The cell treatment methods accordmg to die present invention may also be apphed to m vitro techmques m order to control cells or select cell subpopulattons. Typical applications include, for example, genetic engineering clonal selection for temperature shock resistance genes, which may be either a primary goal or a marker gene for a linked trait. Another organ of mterest is the skin, which may have tumors (malignant melanoma, basal cell carcinoma, etc ), psonasis, viral, bactenal or fungal infection, inflammation, other immunological or autoimmune disorder, loss of elasticity, angioma, and odier conditions. The skin is of particular mterest because of the ease of external access to d e surface Therefore, for example, a stream of steam, laser beam or mfrared source may be apphed to die skin, in a manner which would quickly raise the temperature or the surface and possibly a region below the surface. In contrast to types of known treatments, die temperature nse is carefully controlled to avoid ablation or burning, while the heating is nearly instantaneous. The careful control is exerted, for example in die case of steam, by controlling the partial pressure of the steam and performing the treatment within a conttolled environment, such as a hypobanc chamber or enclosure In the case of laser, the pulse energy and repetition rate, as well as particular wavelength of die laser, e.g., CO2 with 10.6μm wavelength, may be empincally determined for an effective tteatment. In die case of odier electromagnetic waves, the field strengtii and duration of exposure are carefully conttolled to effect a desired treatment. THE RTCP PROCESS The technologies mclude die use of an apparatus which atomizes a fluid to a uniform small droplet size and subjects die droplets to a treatment. The process treatment passes the droplets through a steam chamber at controlled temperature, which results in a rapid heatmg and diermal equihbnum of the droplets. The droplets are expelled from an atomizer nozzle at high velocity, so that the residence time in die steam chamber is limited. Since the maximum temperature is ttghdy conttolled, tins allows precise treatment parameters based on droplet size, velocity, steam temperature and pressure, and die presence of gasses other than water vapor. The treatment also is influenced by d e deceleration of the droplets after tteatment, a small dilution factor due to condensed steam, and die cooling of the fluid droplets after tteatment. The equilibration to the steam temperature is so rapid, in fact, due to die high latent heat of vaporization of steam, that a diermal shock is generated in die droplets. This rapid nse in temperature is accompanied by a mechanical expansion, which generates a mechamcal shock wave m the droplet. The steam condensation also produces an osmotic "shock", with up to 10- 15% dilution, synchronized with die diermal-induced shock. Finally, the droplets are atomized, pass dirough the steam chamber at a velocity of about 20 meters per second, and are decelerated, for example by impact, resulting m a further synchronized mechamcal shocks. This techmque has been shown to kill bacteπa and spores with maximum process temperatures of 45-55C, under conditions which do not significantiy denature milk protems or most lntracellular protems. Thus, this techmque is now bemg developed for commercialization as an effective milk sterilization techmque. Bactenal cells subjected to tins process and which survived were found to have persistent morphological changes m colony growth, which may indicate genetic or regulatory response to the RTCP process. Usmg a Pasteurization system accordmg to die present mvention, many log reductions m E. coh were achieved, for example a reduction of from 10 6 per mil hter to the limit of detectabihty was achieved. Bactenal spores (B. subtihs) are also reduced, aldiough possibly with lesser efficacy, for example a two log reduction (1% of onginal concentration) is achieved. It is beheved d at further refinement of the present system and metiiod will prove more effective against these spores, and prove effective to kill or produce a response m vanous types of viruses, bactena, fungi, protozoans, animal cells, and plant cells. The existence of orgamsms which survive treatment is clear evidence of die gendeness of treatment, and therefore that the treatment may be modulated to effect vanous survival fractions, and selective treatment of cell populations. While strains which are desired to be treated may be found which are resistant to die system and med od accordmg to the present mvention, supplemental metiiods may also be employed to treat the same medium, such as pulsed electnc fields, oscillating magnetic fields, electron ionizing radiation, intense hght pulses, actinic hght or other visible or ionizing electromagnetic radiation, and high pressure treatments. Thus, treatments may be combmed to effect complete Pasteurization or sterilization or more selective cell changes. See, Zhang et al, supra, Mertens et al, "Developments m Nontiiermal Processes for Food Preservation", Food Technology, 46(5):124-33 (1992), incorporated herem by reference. The parameters of a bulk medium steam treatment process which control the efficiency mclude starting and ending temperatures, steam overheating, rate of temperature nse, degassmg procedure (if any), pressure, pre- or post- treatments, pH, droplet size and distribution, droplet velocity, and equipment configuration. Presendy, systems operable for milk Pasteurization have been tested usmg vanous parameters. For example a test has been conducted widi a temperature nse from about 46°C to about 70.8°C, with a milk pH of 6.60 (start) to 6.65 (finish), and a dilution of 2.5%. Droplet size is preferably about 0.2-0.3 mm. The rate of temperature nse is, for example, in excess of 1500°C per second, and more preferably above 2000°C per second. Under these conditions, widi a starting bactenal and spore concentration of 10,000 spores per ml, the final concentration was 12 per ml. Thus, a reduction of about d ree logs was achieved under these conditions, widiout, for example, sedimentation of milk protein or noticeable alteration in taste. The bulk medium steam treatment apparatus accordmg to die present mvention provides a rapid temperature nse by subjecting relatively small droplets of less than about 0.3 mm to dry steam (non-supercπttcal) at a partial pressure less than about 760 mm Hg. For example, with a low partial pressure of non-condensmg gasses (e.g., less tiian about 100 mm Hg, and more preferably below about 50 mm Hg), the partial pressure of steam is about 0.3-0.8 atmospheres (e.g., about 225-620 mm Hg). The steam is saturated, and thus the temperature of the steam is held at a desired final temperature, e.g., 40-75°C. The steam temperature-pressure relationships are well known, and need not be reviewed herein. Droplets of medium including cells to be treated are atomized under force through a nozzle, mto a reduced pressure reactor chamber containing die steam. Under tins partial vacuum, residual gasses are drawn out of die droplet, which may form a boundary layer, reducmg heat transfer rate; therefore, it is preferred that the bulk medium to be treated is degassed pnor to treatment. Along its path, the droplets contact steam, which condenses on die relatively cooler droplets and heats die droplets dirough release of the latent heat of vaporization. As the steam condenses, d e droplets are heated, until tiiey reach the equihbπum temperature of the steam, at which time mere is no further net condensation of steam. The droplets will not get hotter than the steam in die chamber, so that the steam temperature sets the maximum temperature. However, depending on reactor configuration, the droplets may not reach equihbnum, and dius may reach a maximum temperature somewhat cooler then the steam. Of course, the initial interaction of die droplet with die steam will produce the highest temperature change rate, so that the reactor system may be designed to operate at a steady state which does not achieve equihbnum temperature In this case, however, parameters should be ttghdy controlled to assure complete treatment without overtreatment, and dius a maximum temperature above a desired level. The condensation of steam on the droplets induces pressure variations, or more properly steam partial pressure variations, witiiin the reactor. In order to prevent a buildup of non- condensing gasses dirough outgassmg or rmpunties, a vacuum pump may be provided which continuously withdraws gas, with a port near the droplet injection nozzle, removing me non- condensing gasses and some steam. Preferably, however, the product to be treated is fully degassed pnor to entry mto the reactor, and dius tiiere will be little or no buildup of non- condensmg gasses which require evacuation from the reaction vessel dunng processmg. The droplet rapidly equilibrates with die steam temperature under die pressure conditions, over a distance of less than one meter, for example within 70 mm from the droplet injection nozzle. The so-treated droplets are then collected, and may be immediately cooled, dius limiting any adverse effects of long-term exposure to the steam temperature. In one embodiment, the reaction vessel is provided with a number of zones which maintain steady state distinction. For example, m an initial portion, a low absolute pressure is maintained, degassing die droplets In a subsequent portion, the droplets are contacted widi steam, resulting m a rapid temperature nse of the droplets to effect the desired treatment. In a final section, a low steam partial pressure is maintained, allowing vaporization of water from the droplets, allow g flash cooling In this manner, the time temperature product may be held at very low levels, effecting a rapid temperature mcrease followed by a relatively rapid temperature decrease In order to provide separate temperature zones within die reactor, an external energy source within the reactor may be provided, such as infrared radiation source, to maintain steam temperature. Zones may also be separated by baffles which allow droplets to pass, while providing a gas flow restnctton. The steam in one preferred embodiment is provided by a steam generator, which boils, for example, potable or distilled water. This water is degassed pnor to use, so that the steam contains few lmpuπties and almost no non-condensmg lmpuπties. The steam generator may be at any temperature above the final temperature, e.g., 150°C, as the diermal treatment of the droplets denves mainly from the latent heat of vaporization of the droplets, and very little from the absolute temperature of the steam Preferably, the steam is saturated, which will define its temperature in a given atmosphere. If the steam is sub-saturation, condensation of steam on die droplets will be impeded. If die steam is supersaturated, it will itself form droplets and impede die process, in addition to diluting die medium. Process temperature control will also be adversely affected, and may be less predictable. Thus, the mass flow rate of the saturated steam entering mto the treatment system (in relation to the product flow rate and any withdrawal of steam or external heat transfer), controls the process treatment temperature. In the case of an over-pressure steam generator, the mass flow rate is restncted to prevent the tteated droplets from reaching too high a temperature, or supersaturatton conditions. The steam is injected adjacent to die patii of d e droplets being treated, to ensure equilibration by the time the droplet reaches the terminus of the reactor. Due to boundary layer effects of the droplet, due to, for example, non-condensmg gasses, as well as diffusion limitations, die temperature nse is not mstantaneous. However, usmg the system in accordance widi the present mvention, it has been found that temperature nse rates in excess of 2000°C per second, or even 7600°C per second, may be achieved, which are sufficient to inactivate bacteπa, and thus will effect may different types of cells and cellular structures. It is noted diat steam has a latent heat of vaporization of 540 cal/ml; therefore, a 5% ratio of steam to aqueous fluid to be processed will result in an approximately 27°C nse in temperature. The resultant 5% dilution may be inconsequential, or remedied in a later step. In the bulk medium steam tteatment device, d e medium is sprayed dirough a nozzle as a stream of small droplets mto a reaction vessel. The size of these droplets is preferably less than 0 3 mm, though if the droplets are too small they may present other difficulties, such as poor tra j ectorv control, e.g., from low inertia, loss of velocity, e.g., due to drag, Browman motion, coalescence, and die like. Further, reduced droplet size may reduce potential tiiroughput. In addition, since, if die droplet is too large, each drop of die medium may not be effectively treated, die droplet size distribution should include only a small umber of larger droplets, e.g. less tiian 1% of greater than 0.45 mm. Steam, which is produced in a steam generator, from, e.g., potable water, is supphed to d e reactor vessel through a nozzle or array of nozzles. Steam condenses on die droplets, giving up its latent heat of vaporization to the droplets. The magnitude of heat transfer dunng condensation is very high, so that die speed of heating reaches several thousand degrees Centigrade per second. Therefore, m the several milliseconds it takes for droplets to travel through a reaction vessel, the temperature is raised substantially, effecting cellular alteration, e.g., bactenal mactivation, accordmg to die present mvention. The steam is deπved from a boiler. Tight control of temperature may require a high temperature boiler with a control valve near the reactor vessel. In other words, in order to ensure adequate flow of steam mto die reactor, an excess capacity should be available from the boiler. Control is effected near the reactor, to avoid time response delays or oscillation. The water in die boiler is preferably degassed to eliminate non-condensable components. The boiler may have a superheater at its oudet, to heat the steam over a condensation equihbnum level. The steam is mjected mto die reactor vessel through a number of steam mjection ports, spaced along die patii of die droplets within the chamber, so that die region distant from the fluid mjection port mamtams a relatively constant water vapor pressure. Thus, dependmg on die desired conditions, effective Pasteurization may be obtained widi as low as between 2-5% by weight steam, condensed on die fluid droplets to achieve the temperature nse. There are temperature gradients m die reactor chamber, primarily near the mjection nozzle. Since die steam condenses on die droplets, a partial vacuum is created m die region around d e droplet, until die droplet reaches a temperature m equihbnum with the pressure, e.g., around 55°C at 0.5 atmospheres, and thus die vapor pressure equalizes. At equihbnum, die net condensation ceases, and d e droplet remains m equihbnum. The steam consumption is significantiy lesser than m known ultra high temperature Pasteurization processes. Assuming die temperature of heat treatment apphed to milk is to 60°C, the temperature of milk upon entering the reaction vessel equal to 6-8°C, then die required temperature nse will not exceed 55°C. It will require about 55 Kcal for the heat tteatment of one kilogram of fluid medium. As die condensation heat of one kilogram of steam is equal to 540 Kcal (540 cal/ml), only about 0.1 kilogram of steam will be required for condensation, ι.e., only 10% of the mass of the product subjected to processmg Obviously, lesser temperature nses will require less steam. The treated fluid medium, which has been shghtiy diluted witii condensate, is collected on die bottom surface of the reaction vessel and tiien is supphed dirough a special vent mto the dischargmg tank. The collected medium is subjected to a vacuum treatment, evacuating gases (air) and steam from the discharge, dius eliminating excessive water, cooling the fluid medium through water evaporation, as possibly through an external cooling system. The fluid medium may men, for example, constitute a final product or be used as part of a medical treatment. In a typical bactencidal treatment system, a temperature nse of a liquid to be treated is from about 25°C to about 55°C. For example, m a reactor 30 cm high, with a droplet velocity of 20 m/sec, the residence time will be about 15 mS. Thus, assuming an inlet temperature of 25°C and an oudet temperature of 55°C, the temperature change is 30°C over 15 mS, or about 2000°C per second. Typically, the temperature nse will not be linear, nor will equilibration require the entire reactor length, so diat the maximum temperature nse rate will be well m excess of 2000°C per second. The liquid to be treated may be degassed pnor to processmg, to prevent accumulation of non-condensmg gasses widiin the steam treatment reactor and resultant alteration of the diermodynamic operating pomt. Further, by degassmg die liquid pnor to interaction widi the steam, d e interaction witii, and condensation of, steam on die fluid droplets is facilitated. Preferably, non-condensmg gasses are kept to less than about 50 mm Hg, and more preferably less than about 20 mm Hg Alternately or additionally to degassmg pnor to dropletization, the fluid may be degassed widim a first region of the reactor, under relatively high vacuum, after atomization, with subsequendy reaction with die steam m a second portion of die reactor Thus, due to die gas withdrawal m the upper portion, and condensation of the steam onto die relatively cooler droplet stream, steam will tend to flow from the second portion to the first portion of the reactor. Preferably, a baffle is provided between d e two regions, with a relatively high density of fluid droplets to be tteated, present m the transition region between the two portions, so that the steam condenses on die fluid droplets in diis region, maintaining the pressure differential while effectively treating the droplets Thus, steam vapor diffuses toward the fluid mjection port. In general, since the treatment chamber vessel operates at a maximum process temperature below 100°C, the pressure within d e reactor will be below atmosphenc pressure. For example, with an operating temperature of 55°C, the chamber will be held at approximately 0.5 atmospheres, or 380 mm Hg Thus, die pressure in die chamber determines the operating temperature: if the pressure is too high, the necessary temperature to achieve that vapor pressure of steam mcreases or steam condenses, raising die temperature of the reactor, and vice versa. This condition is considered "wet" The control over processmg is thus primarily exerted by the net mass flow of steam mto the reactor. As stated above, a vacuum pump may be provided which exhausts non-condensmg gasses and may also withdraw excess steam, allowmg an additional control parameter and further allowmg a non-equihbnum steady state to exist. For bactencidal treatment, non-condensmg or "dry" treatment conditions are preferred. The walls of the reactor vessel should be maintained at least at or s ghdy above the final operating temperature, to avoid condensation of steam on die wall and unnecessary product dilution This may be done by any suitable heating system. In fact, a number of methods are available to prevent droplets which are insufficientiy treated due to, for example, coalescence mto large droplets or statistical variations droplet size dunng atomizatton, from contaminating the tteated product. For example, the droplets may be electrostatically charged, and tiien normally diverted from a direct path. Droplets of too large a mass will be diverted less, and may be separately collected. Alternately, an entire stream segment may be diverted if a flaw (untreated or untreatable portion) m the treatment is detected. For example, an optical detector may detect a large droplet traversing die reactor and divert the oudet for a penod of time to flush any contaminants. An electrostatic or magnetic diversion system may also be employed to electrostatically charge droplets and dien separate large droplets from small droplets. It is beheved d at, as long as sufficient steam is present, small droplets will be effectively tteated, while the persistence of bactenal contamination dirough tteatment is beheved to be related to die existence of large droplets. Thus, by eliminating or preventing large or untreated droplets, the effectiveness of die treatment is maintained. The reactor may also mclude a second form of treatment, such as ultraviolet radiation, which may be supphed by ultraviolet lamps illuminating widiin the reactor. Since the droplets are small, die hght penetration will be high, thus ensuring full coverage. Likewise, microwaves or other radiation may me used for auxiliary heating of droplets to the desired temperature, or for an electromagnetic field treatment of the droplets. Where the fluid to be tteated contains otiier volatile compounds, such as edianol, such vapors mav evaporate from the droplets, especially at elevated temperatures. This produces two effects First, a boundary layer is created by die net outward mass flow, which may impede steam contact and heating Second, dependmg on die temperature and pressure, the heating of the droplet may be counteracted by die loss of heat of vaporization of the volatile component. Therefore, care must be taken to ensure that die fluid droplets do not reach the end of die reactor and pool pnor to bemg raised to the desired temperature, or that die temperature nse rate is insufficient. It may also be necessary to mject alcohol vapor with the steam to maintain equihbnum conditions in die reactor. It is noted diat the reactor may also be used to reduce or vary alcohol concentrations of the fluid bemg tteated, by varymg the treatment condittons. For example, alcohol vapors may be withdrawn and captured dirough a vacuum pump, along witii non-condensmg gasses and some steam. This allows the production of a "hght" alcohohc beverage, while killing yeast or other organisms. It is also noted diat vanous non-biological compositions may have glass transition temperatures m the 25-300°C temperature range, and tiierefore the present apparams may be useful for usmg steam to rapidly alter a crystalline state of, e.g., these polymers, copolymers, block copolymers or interpenetrating polymer networks This rapid limited heating may be advantageous, for example, to rapidly initiate a chemical reaction while mamtainmg a mechamcal configuration of a bead, for example, if the time constant for the chemical reaction is comparatively fast with respect to the thermal diffusion time constant. Further, m larger droplets, an external polymerized shell may be formed around an unpolymeπzed mtenor. MODIFICATION OF CELLS The RTCP techmque, under appropnate conditions, has die ability to alter cells, without significant denaturation of most protems. There are three mechamsms postulated to exert effects on the cells: (a) Heating Cells are heated m a rapid (millisecond πse-αme) and conttolled manner to a desired temperature, and held for a short penod. Cooling is slower, on the order of seconds. Millisecond heating causes two potential effects. The thermal expansion wave, as well as differential coefficients of diermal expansion, produce a mechamcal stress directed on die membrane or cell wall. The cell membrane may also transition through a glass transition temperature faster than die cell can accommodate, resulting m membrane disruption. For example, the glass transition temperature of dipalmitoyl phosphatidyl chohne, by scanning differential calonmetry, is about 41 °C. "Physical Properties and Functional Roles of Lipids in Membranes", Biochemistry of Lipids, Lipoproteins and Membranes (1996). (b) Osmotic Stress The heatmg effect is earned out by condensation of saturated water vapor on relatively cooler atomized droplets of medium The dilution may be m the range of 1-10%, which occurs synchronously witii the heating. This osmotic stress also acts on the membrane. (c) Mechamcal Shock The medium, for tteatment, is forced dirough an onfice, causmg uniform atomizatton as a spray of droplets at high velocity, which pass through a steam chamber, reaching equihbnum temperature with the steam before hitting a distal wall. The atomizatton and deceleration after tteatment both produce significant mechamcal stresses on the cell. In many medical treatments, it may be desired to avoid killing die cells, but rather to exert a stress to which the cell responds. In tins case, the RTCP system is tuned to provide a controlled thermal effect, limited osmotic stress (associated with the temperature nse), and minimized mechamcal stress Thus, mechamcal cellular disruption, an effect which is available through other means, is minimized. In contrast, where it is desirable to kill cells, each of the effects is maximized, limited by diermal denaturation effects and turbulent alterations of the media. In some cases, killing of a partial cell population may be sufficient, m which case the tteatment condittons are modulated to minimize undesired side effects, such as dilution, turbulence, medium protein precipitation, etc. In other cases, it is desired to kill all of a cell population or stenhze the medium. In tins case, the treatment conditions are estabhshed to kill the desired cells with a desired statistical margm. It is therefore an object of the present invention to provide a system and metiiod for fusing hpid membranes, compnsing the steps of providing the membranes to be fused in a liquid medium; and heating die liquid medium, containing die membranes to be fused, at a rate and dirough a range sufficient to cause a discrete transition m at least one of the membranes, such mat die membranes fuse. It is also an object according to die present mvention to provide a system and mediod for disrupting hpid bilayers, compnsmg die steps of providing the hpid bύayer in a polar medium; and heating the polar medium at a rate and dirough a range sufficient to generate a shock wave in the hpid bilayer to reduce an integnty thereof. It is a further object accordmg to die present mvention to provide a system and mediod for fusing a hposome with a cell, compnsmg the steps of providing a hposome and a cell m mutual proximity in a physiological medium; and heating die physiological medium at a rate sufficient and dirough a range appropnate to cause an abrupt glass transition in a portion of at least one of the hposome and d e cell, to cause a fusion thereof. It is also an object according to d e present mvention to provide a system and method for processmg a hpid bilayer structure, compnsmg the steps of providing a hpid bilaver structure m a liquid polar medium; and heating die liquid polar medium at a rate sufficient and dirough a range appropriate to cause an abrupt glass transition in a portion of the hpid bilayer structure to alter a mechamcal configuration thereof. One of die membranes may be of a eukaryotic orgamsm, for example a mammal. The cell is preferably a circulating formed blood component, such as an erythrocyte, lymphocyte or phagocyte, or even platelet. The cell may also be an abnormal cell, such as a malignant cell, immortalized cell, cell mfected with a bactena, virus or other lntracellular parasite, a cell having a genetic or environmentally mduced deficiency or surplus of rmneral, nutnent, enzyme or other composition. The system may be used to treat a smgle type of membrane-bound structure, a pair of structures, or a mixture of a number of structures For example, cells may be fused wid two or more types of hposomes. The membrane may also be an engineered structure, such as a hposome or vesicle. The engineered structure may have a specific composition on its surface (outer or inner) or intenor. The composition may be a pharmaceutical, nutnent, oxidant or anttoxidant, cytokme, enzyme (e.g., glucose-6-dehydrogenase), protem, receptor, receptor binding hgand, receptor agomst or antagonist, hormone, gene regulatory agent, antibody or portion diereof, cytotoxic agent, redox state altenng composition, pH altenng composition, viral protem, viral receptor protem, nucleic acid (e.g., nucleic acid encoding at least one gene or regulator). For example, hposome containing phosphatidyledianolmmes, diacylglycerol, ethanol, short chain fatty acids, and/or hpid peroxides be treated, for fusion with a cell. After treatment, the product may be stored, for example for hours, days or longer, or further processed or employed m a medical treatment. The product may also be used m industrial or biotechmcal processes The cells an/or medium may be injected or infused mto an animal, for example intravenous or directed to lymphatic pathways. Duπng or in conjunction widi heat treatment, the membranes or medium may be subject to odier conditions, such as oxidizing or reducmg agents, anttoxidant (free radical trapping) agents, photomc or microwave radiation tteatment, turbulence or shear forces, or the like. A non-diermal bactencidal treatment may therefore be apphed in conjunction with the heat treatment. The medium may be filtered to remove most bactena. As a result of heat tteatment, the membrane may be reversibly altered, irreversibly damaged, fused or otiier alterations, m addition to changes due to components added or removed from the membrane during the process. Thus, a cell may be killed or remain alive as a result of the treatment. One set of embodiments according to die invention achieves sterility, for example killing prokaryotic and eukaryotic cells, including mycoplasma. According to one object of the invention, two different membrane structures are subjected to tteatment, one membrane structure having an effective glass transition temperature below an average glass transition temperature of the odier. One of die structures may be homogeneous while the other is heterogeneous, e.g., a mosaic domain structure as hypothesized by Singer and Nichols. The heat treatment my therefore induce a gel to liquid state transition in at least a portion of one membrane. The temperature rise rate may exceed an accommodation rate of the membrane. The rapid heating may, for example, cause at least a portion of a hpid bilayer membrane to enter a non-bilayer state. The heating may also cause a non-linear change in packing density of molecules forming a membrane. In order to improve the efficiency or selectivity of die process, a cell may be incubated under such conditions as to alter a cell membrane hpid composition. The temperature rise rate is, e.g., greater than 100 C per second, and may be greater than 1000 C per second. The temperature rise may be greater than 10 C, for example 25 to 40 C, and die maximum process temperature may be less man 55 C, preferably less than 49 C, and possibly as low or lower than 43 C. The heat tteatment preferably does not substantially denature cellular proteins, although under certain conditions, denaturation of at least certain proteins may be desired. The medium may be a physiological solution, milk from a mammal, human milk, milk or blood from a transgenic mammal, blood plasma or serum, fermentation broth, water, saline or other fluids. The heating may be effected, for example, by water vapor or steam, which is preferably "superheated" or "dry" to reduce spontaneous condensation. An inert, non-condensing gas may be present during tteatment, or the tteatment may be conducted widi low non-condensing gas levels. Thus, non-condensing gasses may be added or removed during treatment. The medium is preferably degassed prior to tteatment. The medium is preferably atomized prior to heating. The atomized medium is preferably heated while moving at a velocity of at least about 10 cm/sec, preferably at least 100 cm/sec, and more preferably 1000 to 2000 cm/sec or higher. The medium may be subject to mechanical forces synchronized wid and independent of d e heating. The apparams has, for example, a processmg capacity of between about 0.25 - 125 ml per minute, and preferably a processmg capacity of between about 1-25 ml per minute. The apparatus may have a transparent treatment chamber, for example made of glass, e.g., borosihcate glass or of fused quartz. The apparams may also mclude an automated or assisted cleamng cycle to achieve sterilization and/or to remove deposits. The apparams preferably has a control, the control bemg programmed to detect a treatment aberration. In one embodiment of die mvention, two cells are fused in order to achieve a hybnd. Such a process mcludes tteatment of a mahgnant or immortalized cell and differentiated cell to result m a cell having differentiated charactenstics, such as specific gene products, e.g., a sigmficant secreted gene product, such as an antibody. The resulting cell hne may tiierefore produce, e.g., a monoclonal antibody from an lmmunoglobuhn secreting hybndoma. Otiier objects and advantages of the present mvention will become apparent from a review of the drawings and detailed descnptton. BRIEF DESCRIPTION OF THE DRAWINGS The preferred embodiments of die mvention will be explained by reference to the drawings, in which: Fig. 1 is a simplified diagram of a reactor according to die present mvention, Fig. 2 is a detailed diagram of a reactor accordmg to the present mvention; Fig. 3 is a partially schematic diagram of a processmg system accordmg to die present mvention; Fig. 4 is a partially schematic diagram of a processmg system, showing details of sensor systems for control, accordmg to die present mvention; Fig. 5 is a sermschematic diagram of a processmg system accordmg to die present mvention employing continuous mode degassification; Fig. 6 is a schematic drawing of an RTCP apparatus similar to those shown in Figs. 1-4; Fig. 7 shows operational parameters of the prototype apparams accordmg to Fig. 1 operating at 60°C maximum temperature and overheated steam temperature of about 100°C; Fig. 8 shows operational parameters of the prototype apparams accordmg to Fig. 1 operattng at about 50°C maximum temperature; Fig. 9 shows a hposome membrane having cytochrome C mserted tiierein; Fig. 10 shows an abrupt phase transition m an experimental system; Fig. 11 shows a schematic drawing of a cell membrane; Fig. 12 and 13 shows reduction of E. coh m milk in die reactor accordmg to die present mvention under vanous condittons; Figs. 14 and 15 show schematic diagram of a Pasteurizer pilot plant according to d e present mvention as a flow diagram and process flow diagram, respectively; Fig. 16 shows a vaπety of hpid phases in aqueous medium, including bilayer and unstable states; Fig. 17 shows two possible mechamsms of membrane fusion; and Fig. 18 shows die interaction of antibodies on die surface of a hposome with complementary cell surface structures. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT The preferred embodiments of the mvention shall now be descnbed witii respect to the drawings, where identical reference numerals in the drawings indicate corresponding features. EXAMPLE 1 As shown m Fig. 1, the apparams mcludes a steam generator and superheater, a pressunzer for the control and test solutions, a degasser, a steam treatment chamber, and a sample collection system. Fig. 1 shows a simplified diagram of a steam condensation reactor vessel accordmg to die present mvention. The reactor is formed of an upper body 203 and a lower body 204, with a seal 205 therebetween. A fluid to be treated, which may be a growth medium, milk, or blood component, is degassed accordmg to conventional procedures, preferably to a level of at most 50 mm Hg non-condensable gasses, and more preferably to a level of no more than 20 mm Hg non-condensable gasses. The degassed flmd enters the reactor at approximately 22°C through a conduit 201 having an atomizer, which produces a spray of small flmd droplets, dispersed m die reactor space 210. The pressure m the reactor is held at approximately 0.5 atmospheres by a vacuum control system 207, which is provided widi a baffle 206 to prevent withdrawal of flmd to be processed. The baffle 206 also serves to insulate die reactor space from the upper body 203. The reactor space is filled widi steam, e.g., substantially pure water vapor from steam injectors 202. The steam is provided at equihbnum, and dius die vapor pressure of the steam at the temperature of the reactor, i.e., approximately 55°C, is equal to the pressure of the reactor. Under such conditions, die steam will tend to condense on die fluid droplets, releasmg their latent heat of vaporization, heating die droplets, until the droplets reach the temperature of the steam. As the steam condenses, a partial vacuum is created around die droplet, causing a net mass flow mto die droplet Depending on die exact reactor conditions, up to 10% by weight of steam may be absorbed, but generally the amount will be limited to 2-5%. The droplets are ejected from the atomizer at approximately 20 meters per second. The total height of the reactor space is approximately 30 centimeters. Thus, the residence time of droplets within die reactor, before hitting die lower body 204, is at most about 15 mS. Therefore, the temperature of die droplets nses from 20°C to 55°C m about 15 mS, thus yielding a temperature nse rate of at least about 2300°C per second. In fact, the maximum nse rate will likely be higher, because the steam equilibrates with die droplets before reaching the end of die reactor As the droplets hit the lower body 204, an accumulation and pooling takes place, and die flmd drams from the reactor space through exit port 208, assisted by gravity. Fig. 2 shows a reactor in more detail. The reactor is similar m operation to the reactor detailed in Fig. 1 The reactor is formed of a cover 302, and a shell 301. A lower comcal base 313 is provided below die shell 301 In tins case, the flmd to be processed is mjected dirough plenum 306, widi an atomizer structure 312, which produces, e.g., 5 micron flmd droplets m a fast moving stream 309 Steam is mjected dirough a dual manifold system 305, which mcludes senes of central, upper mjection ports 308, which provide a relatively high flow of steam near the atomizer structure 312, and a senes of nsers 304 which allow for reduced macroscopic pressure gradients within the reactor. In order to prevent undesired preheating of the flmd, a cooling jacket 307 is provided having circulating cooling water around die plenum 306. The fast moving stream 309 reacts with die steam mjected dirough d e upper mjection ports 308 and the nsers 304, and becomes a heated flmd 310 at approximately the steam temperature. The heated droplets continue dirough the reactor, and reach equihbnum with the steam, as equilibrated droplets 311, and condense against die comcal base 313 and exit the reactor through exit port 314. Preferably, a vacuum is drawn on the exit port to exhaust any accumulation of non-condensable gasses from the reactor dunng operation, to mamtam the reactor m a steady state condition. Table 1 shows vanous operating parameters of a preferred reactor design accordmg to the present mvention. TABLE 1 Parameter Milk Vapor Flow Kg/hr 1000 100 Pressure m entrance of Processor 0.4 0.1 Steam temperature m Processor, °C 40-100 Processor volume 0.1 48.8 Fig. 3 shows a bacteπcidal system incorporating the reactor 401. In this case, the flmd to be tteated, e g., milk, is provided m a degassification chamber 402, provided with a control valve 411 to a vacuum pump 409 The flmd is transported widi a pump 407, dirough a valve 406, to the mjection plenum of die reactor 401. The reactor 401 is also connected to die vacuum pump 409 dirough a separate valve 405 for startup cleansmg of the reactor 401 and scavenging of non- condensable gasses. Pooled flmd accumulates at die bottom of die reactor 401, and is drawn to a processed flmd holding tank 404, where it may be drained through valve 410 The flmd holding tank is also connected to die vacuum pump through valve 408, to allow a gradient for withdrawing processed flmd from the base of the reactor 401 A steam generator 403 provides steam through control valve 412 to the reactor 401, controlling the temperature in the reactor 401, e.g., between about 40°C and 90°C, dependmg on the desired condittons. EXAMPLE 2 Fig. 4 shows a bactencidal system similar to the system descnbed m Example 1 , witii die identification of elements for testing and conttollmg vanous condittons widim the reactor system. In tins system, the steam generator 403 is provided widi a sight glass 428 for determining water volume, diermocouples T8 and T9 for determinmg temperature, pressure gage 437 and an electrical heater 428. Water enters the steam generator 403 from reservoir 427 dirough valve 426. The degassification chamber 402, m this instance, shows a system which partially replaces air, with argon 424, through control valve 411. Thus, according to this embodiment, the motive force for dnving the medium from the chamber 402 through die nozzle is die argon 424 pressure. While argon 424 is a non-condensable gas, die amount which dissolves is relatively low duπng a treatment penod. A tiiermocouple T10 and pressure gage 423 are also provided. A heater 430 is provided to heat die outer shell of the reactor 401. The steam is mjected dirough a pair of control valves 412a, for an annular manifold and 412b, for a nser manifold, mto die reactor. A pair of thermocouples T6 and T7 are provided to measure the steam temperature. Within the reactor, a set of thermocouples TO, Tl, T2, T3, T4 and T5 allow determination of temperature gradients witinn die reactor at steady state conditions. To mamtam vacuum conditions witinn die reactor, the vacuum pump (not shown m Fig. 4) acts dirough valve 422 and hne 421 dirough water trap 420 and valve 405. The vacuum also acts dirough valve 434 to draw pooled flmd from the reactor 401, through valve 431. Valves 432, 433 and 435 allow use of sample 436, witiiout disrupting reactor operation. Figs. 12 and 13 show results of testing the bactencidal effect of die reactor system accordmg to the present mvention. In these figures: no is the initial concentration of E. coh (Fig. 13) n v is the concentration of bactenal which survive treatment nk is the concentration of killed bactena PH 2 0 1S tne pressure of steam m reactor h is the heat of vaporization of water T s is the saturation temperature of steam in the reactor R is the gas constant (8.31 g/kg K) g s t is the steam flow SH 2 0 ls me fl° w ° processed liquid 0 witiiout degassification of chamber • with degassificatton of chamber □ , Δ with degassification of die hqmd Figs. 12 and 13 dius show d at bactenal kill to survive ratios mcrease with mcreasmg steam pressure (Fig. 12) and that degassificatton of the chamber improves bactenal killing as well (Fig. 13). Fig. 13 also demonstrates die effects of die relationship of flmd flow rate to steam flow rate. Laboratory tests were conducted of vanous fluids containing E. coh, B. subαhs and mixed milk microflora. Tests were conducted of sahne solution, milk, egg yolks, and blood plasma. 90% heating of hqmd occurred within 1.5 to 2.0 mS. Table 5 shows results of E. coh in sahne solution. The tests of other bactena m otiier solutions produced similar results. TABLE 2 Sample Ei nd Temp Start Temp surviving E. coh initial E. coh < No. t , °C o , °C n, % n 0 , 1 ( 1 50 13.2 1.4 2 51 13.6 1.34 0.035 3 52 11.0 0.1 0.035 4 52 11.4 1.3 0.21 5 52 11.4 1.5 6 52 11.4 0.078 0.035 7 53 23.2 1.3 8 56 40.0 1.0 0.11 9 63 37.0 0.018 0.11 10 64 36.5 0.027 0.11 11 30 15.6 0.39 1.8 12 33 20.0 0.42 1.8 13 40 12.0 0.006 14 41 24.7 0.46 1.7 15 42 23.8 0.37 1.8 16 42 17.5 0.43 1.7 17 44 19.8 0.32 1.7 18 50 32.8 0.007 0.22 19 50 31.0 0.006 0.22 20 52 30.6 0.006 0.22 21 59 12.0 0.009 0.21 EXAMPLE 3 Fig. 5 shows a modified bactencidal system, as compared with Example 1, in which at least a portion of die degassification is performed in-line, rather than in primarily in batch mode. Further, the reactor forms a part of the degassification system. A holding chamber 6 is provided for milk 5 A partially decompressed gas space 4 is provided, acted upon by a low vacuum pump 8 through vacuum hne 7, to vent 9. This acts as a first stage of the degassification process. Fresh milk is fed to d e holding chamber through an inlet conduit 2 having a valve 63 and inlet port 3. The partially degassed milk 11 is fed dirough fluid feed line 10 to a feed pump 53, dirough line 13, to a vortex degassification system 50, having vacuum pump 62 through vacuum line 61. The milk 51 swirls under vacuum conditions to exit port 52, and is pumped into the processor with pump 12. The milk is then atomized widiin the reactor vessel, of the processor shell 28 and die conical pooling region 32, behind a baffle 55. The region proximate to the atomizer 54 is drawn under vacuum by vacuum pump 60 dirough line 59, to about 20 mm Hg pressure. The atomized droplets 56 have a high surface area to volume ratio, and degas readily under these conditions. The degassed droplets pass dirough an aperture 57 of the baffle 55, and enter the main portion of the reactor vessel, coming into contact widi steam at approximately 55°C. In diis region, equilibrium is not achieved, and a net mass flow of steam will tend to be drawn upward through the aperture. However, since the droplets are cool, i.e., the milk stream is provided at approximately 22°C, and d e droplets are further cooled by die degassification treatments, the steam will tend to immediately condense on d e droplets, causing a rapid heating. The steam 29 is injected into die reactor through a vertical steam distribution riser system 27, fed by steam distribution manifold 26, dirough steam injection line 24, pressure regulator 22, with relief port 23, from steam generator 18 having steam space 119. The steam generator is heated electrically by electrical heater 20, controlled by conttol 40 widi temperature sensor 41 and power source 42. Water is fed to die steam generator 18 through water feed line 17. Processed milk 58 contacts the conical neck 33 of the reactor and pools 34 at the lower portion, and is withdrawn through oudet line 35, dirough pump 36, to processed milk oudet 37. EXAMPLE 4 A pilot plant reactor system is shown in Figs. 14-15. This system allows optimization of process parameters, and is capable of continuous operation, however, as a pilot plant, is generally is operated widi a 15 liter fluid reservoir. The system operates on the principle of heating droplets using condensing steam in a vacuum chamber, which is held a constant subatmospheric pressure by a vacuum pump. The pressure within the steam generator is measured with a compound pressure and vacuum gauge 612. The atomization of the fluid is implemented dirough a nozzle, into which the product is fed under die pressure, for example generated by and inert gas (argon) source, at a pressure in excess of 4-5 atmospheres, through gas/vacuum valve 613. The level of water within die steam generator may be determine by viewing die glass level gauge 611 The major components of the system, exclusive of controls, include a steam generator 601, a Pasteurization reactor 602, a raw product tank 603, a Pasteurized product tank 604, a vacuum collector 616, a dram tank 606, a condensate tank 607, and an inert gas feed-in system to the raw product tank 609. The vacuum system mcludes water circuit pump 626 and vacuum oil pump 620, which can operate individually or following the scheme: the gasses from the vacuum collector 616 are pumped out to a vacuum pump 620, and/ or to a water circuit pump 626. In order to avoid water condensation, or to dimmish same, m an oil vacuum pump 620, a steam condenser 621, which has its own water feed-m 622 and feed-out system, is installed between the reactor 602 which undergoes evacuation and die pumping system. The vacuum collector 616 drains to a condensate tank 615. Product steam processmg control feedback is implemented dirough a thermocouple (<1°C resolution) and diaphragm pressure gauges (10 Pa resolution). Thermocouples are installed m the water and steam umts of die steam generator 601, m the reactor 602 near the nozzle, located near the top of the reactor 602 (seven m all) for the purpose of gauging temperatures m a steam-droplet mixture at die product dram hne 631 m die reactor 602, and in die tanks of raw 603 and Pasteurized 604 products. Pressure is measured m a steam collector 632 and m the bottom part of the reactor 634. In addition, it is possible to sample die steam-droplet mixture from the vacuum lines of the reactor 635, 636 for its subsequent analysis on a mass-spectrometer 623 of the mass specttometer system 639. The sample to the mass spectrometer 623 is passed through a mass specttometer sampler tank 618, the pressure of which may be determined by pressure gauge 617. A vacuum pump 619 draws die sample gas mto die mass spectrometer sampler tank 618. The mass spectrometer is connected to a magnetodischarge diode cooled pump 627. Vacuum processmg of the reactor 602 duπng operation is implemented in two locations: m die upper part 635 of the reactor 602, near the nozzle 637 for the purpose of degassmg raw product from tank 603; and m die bottom part 636 through the reactor 602, around a system of shields, which is the mam passage to the vacuum processmg system. Samples of the processed product are taken directiy from the stream of the processed product, mto disposable syringes, through the dram hne 606 of the reactor 602. The Pasteurizer reactor system consists of a number of components. A nozzle 637 (sprayer) for atomizing milk or any other hqmd product to be Pasteurized, mto drops The nozzle 637 is of a standard, centnfugal, dismantling type. The outlet ring 646 of the nozzle 637 is replaceable, its diameter bemg equal to 4.8 mm for the water consumption of 1 liter per second at a pressure 0 4-0.5 MPa and 2 mm for the water consumption of 0.15 hters per second. The vortex segment 647 of die nozzle 637 has the following dimensions: diameter equal to 27 mm, with the height of die cylindrical part equal to 6.5 mm. The vortex forming ring 645 has 6 triangular grooves 3.2 x 3.2 mm at an angle of 45° to die horizontal plane. There is an inlet 648 m the center of the ring 645, the diameter of which is equal to 3.6 mm. When me inlet 648 is closed, die nozzle 637 is operating as centtifugal. When d e inlet 648 is open, operates m a jet- centnfugal mode. The jet-centnfugal mode of the nozzle 637 fills the cone practically to capacity at a dispersion angle of 90°. The purely centtifugal mode of d e nozzle 637 has die center of the cone empty, but die drops are of more homogeneous dimensions. The nozzle has a non-toxic rubber seal 643. The body of die reactor, is attached to die shield 704 and die steam collector 705, with inlets of 5 mm m diameter for steam dispensing die reactor. The placement of die inlets and dieir number are optimized by way of empincal testing dependmg upon die product consumption and die dimensions of its drops. The upper part of the steam collector 705 mcludes two welded pipes 720 for dry (or shghdy superheated for 10°C-20°C) food steam. The non-condensmg gas is evacuated dirough die space between the shield 704 and die outer body 721 of die Pasteurizer reactor 700. Connector 722 serves for evacuating die non-condensmg gases from the bottom part of the Pasteurizer reactor 700 when there is no prehmmary degassmg of the raw product, and die degassmg process is combmed with deaeration. There is a circular groove 723 in die bottom part 706 of the body of die reactor 700 which serves for collecting and dischargmg of the condensate, which is forming dunng steam condensmg on the body of die Pasteurizer reactor 700. The bottom of the Pasteurizer reactor 706 is designed for collecting drops of the Pasteurized product, and its subsequent dischargmg mto the tanks 604, 606, 607 The bottom 706 is sealed widi a rubber rope gasket 724. There are tubes 725 designed for dischargmg condensate from the circular groove 723 located on d e body of die Pasteurizer reactor 700 mto the additional tank. Food hqmd to be tteated m die Pasteurizer reactor 700 is broken up mto small drops (diameter of approximately 0.2-0.3 mm) by the nozzle 637, on which steam condensmg takes place The drop heating speed and the efficacy of Pasteurization is better when non-condensmg gases are eliminated by way of vacuum degassmg. The siphon 726 is attached to die lower part 706 of the reactor's 700 bottom, and has a welded seal for the tiiermocouple. The system features a siphon 726 to which a connection point 714 widi a rubber ring seal 727, has been welded in the upper part of its body. This rubber ring seal 727 enables sampling of the product be taken immediately at die drain line of the Pasteurizer reactor 700 by piercing it wid a disposable syringe. As shown in Fig. 14, raw product 523 with a temperature, for example of 4°C is fed into die tank 521 (constant level tank), and tiien is pumped by die pump 518 through valve 517 into the recuperator 512, where it is heated, for instance, up to 44°C. The heated product is dien directed dirough valves 508 and 505 into die deaerator 501, where it is degassed, widi a vacuum through die valve 502. At this time partial evaporation of the product is taking place and it is cooled down, for instance to 34°C. The deaerated product is discharged from 501 through product pump 506. Valve 504 and level sensor 547 provide die level, which is necessary for normal operation of the pump 506. Pump 506 feeds die product dirough Valve 507 into the Pasteurizer 538. All pumps 518, 506, 546, 530 can have similar parameters: capacity greater than or equal to 1 m 3 /hour, widi a pressure no less than 0.4 MPa. The Pasteurizer 538 reactor is pumped out, reaching the level of pressure approximately 10 Pa through valve 539, and is filled widi dry, non-toxic, saturated steam reaching the level of pressure which correlates with the temperature of saturation, for instance, 68°C. Steam Pressure controller 540, with the help of an automatic steam valve 542, provides steam pressure at the inlet to die Pasteurizer 538 reactor which correlates with the specified temperature of saturation (68°C). The product is broken up to drops of specified dimensions, for example, 0.3 mm, and is heated up by steam condensation from 34°C to, for example, 64°C. The heat-up speed is equal to up to 20-30 diousand degrees Centigrade per second. Through valve 545 and die level sensor 535, the Pasteurized product is pumped out by d e pump 546, and is directed into die recuperator 512 through valves 515, 513 and 514. The product is dien cooled down in die recuperator 512 as low as, for instance 24°C and is further discharged into d e vacuum unit 532 dirough valve 534. Here the product is cooled down due to die evaporation into die vacuum, until it reaches the temperature of the raw product, e.g., 4°C. The cooled down product is pumped out from the vacuum unit 532, dirough pump 530, and is fed dirough a magnetic flow meter 529 and Valve 527 either to the drain line 525, dirough which Pasteurized product is discharged, or into the recirculation hne 524 through valve 526, and dien into die constant level tank 521 dirough sight glass 522. If the temperature of the cooled Pasteurized product is equal to the temperature of the raw product, dien dilution of die product widi food steam is approximately equal to zero. The precise balance between the water which is induced into die product and dien removed from it, is sustained by die Ratio Controller 519, by balancing gas pressure in the vacuum chamber 532. During optimization of die Pasteurization system, automatic steam valve 542 has to be monitored by the Steam Pressure Controller 540 at the input to the Pasteurizer 538 reactor, by temperature monitor at die output from Pasteurizer 538 reactor and die diermal shock controller 536. After this system is optimized, diis valve will be controlled by one of die mentioned controlling mechanisms (most likely the thermal shock controller 536). It is feasible to eliminate the preheating in die recuperator 512. In this case the product is fed through bypass 516 and further on into die deaerator 501 and into d e Pasteurizer 538 reactor. The advantage of this procedure is diat assuming mat heat-up speed is equal, d e maximum temperature of the product at die output from the Pasteurizer 538 reactor will be lower than in a system having a recuperator 512. The drawback, however, is that die extent of deaeration is reduced. It is also possible to operate the system witiiout die deaerator 501. In this case, the product is fed into die Pasteurizer 538 reactor immediately dirough valve 508, while 507 is closed, or through valve 508, valve 505, product pump 506, valve 507, while valve 504 is closed. If recuperator 512 is not utilized, then diere is no need to use product pump 546. In this case the Pasteurized product is discharged from Pasteurizer 538 reactor into die vacuum chamber 532 through valve 545 by the force of gravity. Using die reactor shown in Figs. 14-15, d e following test was conducted. The reactor system, before operation, was subjected to vacuum conditions by a vacuum water circuit pump for one hour to remove residual gasses, down to a pressure of 14 kPa. The steam generator was degassed by heating to 69°C for one hour, and dien all portions of the reactor were steamed at a temperature of 75-100°C, with die vacuum pump turned off. After steaming, die condensate was discharged from the tanks, and die reactor and steam generator hermetically sealed. The reactor was then subjected to partial vacuum and cooled down to 69°C. The steam heater was set to 150°C, with the steam generator set to 65°C. A physiological solution was initially processed by degassing for 45 minutes. This solution was then fed dirough die reactor at a maximum rate of 50 liters per minute. The initial concentration of E. coh bacteria in die solution was 8x10 6 per ml, the initial temperature 20°C, and initial pH = 5.1. After treatment, die bacteria were reduced to 20% of starting values, the final temperature was 47°C, and final pH = 6.1. Nine liters of fluid were treated in 36 seconds, with a consumption rate of 0.9 m 3 per hour. The flmd was pressurized under argon with 4 atmospheres pressure. The average saturated steam temperature within d e reactor was 60°C. The flmd tank was filled with a physiological solution containing E. coh from a sealed bottle. After fill-up, die physiological solution was evacuated dirough a vacuum pump for a penod of 45 minutes in order to degas die product. Argon was dehvered mto die source product tank under a positive pressure of 4.0 atmospheres, and die maximum outflow rate, with die control valve bemg fully open, was estabhshed. The duration for discharge of 9 liters of physiological solution was 36 seconds, which corresponds to a consumption rate of 0.9 m 3 /hr. The initial portion of the processed product, about 1 hter, and die final 1 hter portion were discharged mto die dram tank, because die startup and completion penods may mduce defects m die treatment or be non-uniformly tteated. Dunng the middle portion of die treatment, the product ported mto die processed product tank, from which a 0.5 hter sample was taken directiy mto a hermetically sealed glass vessel. Upon completion of Pasteurization, the steam generator was turned off, and argon was dehvered mto d e reactor and die product was discharged. After discharge, the system was cleaned widi an alkaline solution, followed by rinsing with distilled water. The system was disassembled, examined, subjected to boiling of the disassembled reactor, tanks and removable parts of the vacuum system for 5 hours. After cleamng die surface, the system was reassembled. Based on an analysis of thermocouple data, it is apparent that heating of the droplets occurs within an interval of 70 mm from the nozzle onfice, with a gradient of 0.55°C per mm. Due to die high fluid flow rate, and a relative insufficiency of the power of the boiler, the Pasteurization process was non-stationary, with a divergence of P and Ps. The steam pressure m the steam generator dunng die process was lower than die saturation pressure in the steam generator by a factor of 1.0-1.5 kPa. The temperature m the droplet cone was about 60-50°C, ι.e. the steam was wet. As was demonstrated by further tests, wet steam is not conducive to optimal results. EXAMPLE 5 In order have d e system descnbed m Figs. 14-15 operate m a stationary mode, die following changes were made from the procedure descnbed m Example 4: (1) The power of the steam generator was mcreased to 12 BTU, together with a superheater it amounted to 15 BTU. (2) The centrifugal jet mjector, having a nozzle diameter of 4.8 mm, was replaced by a centtifugal jet mjector having a nozzle diameter of 2.0 mm, thus reducmg flow rate. (3) The geometry of the steam distributor was changed. (4) Sample testing was performed usmg a disposable syringe dunng Pasteurization. A test was conducted as follows: Starting conditions: 10 6 E. coh per ml, temperature 21°C, pH = 5.37, flmd volume 15 hters. Fmal conditions: less tiian 2 E coh per ml, I e , 2x10 6 times the starting amount (the limit of the sensitivity of the detection mediod), temperature 64°C, pH = 6.8. The consumption rate was 150 hters per hour. The steam saturation temperature Ts = 65°C, with die temperature of the superheated steam bemg 77°C. The tests on die air-tightness of the system before the experiment proved that tiiere was no gas ln-leakage. The process was conducted with a temperature in the steam generator bemg equal to 65°C. The steam m the heater was about 10°C higher than die saturation temperature. Before mjecting the hqmd mto die reactor, the pumpmg rate was lowered to such level, so that 10% of the power capacity of the steam generator was expended. When die flmd was mjected, die steam generator automatically switched to 100% power mode. The reduced power mode was maintained for 5 mm. pnor to commencing treatment. Under these conditions, a stationary mode of operation was achieved for 250 seconds. The difference between pressure m the reactor P and die saturation pressure Ps did not exceed 100 Pa. The temperature gradient at the surface of the cone was 2°C per mm. EXAMPLE 6 A standard blood pheresis apparams, available from Johnson & Johnson, is employed m an exttacorporeal reactor system to remove and separate blood components. The leukocyte-nch fraction is diluted 1:10 m degassed 4°C normal sahne, and passed dirough a reactor similar to that shown m Figs 14 and 15, aldiough smaller. For example, the reactor is 120 mm high. Droplets are atomized as 75-100 microns. Steam is mjected mto die reactor to reach a maximum temperature of 35-40°C. flow through the reactor is about 100 ml per minute. The processed leukocytes are remfused mto die patient. Flmd overload is limited by retaining plasma from the pheresis system, as necessary (which may be remfused later), and limiting die duration of the treatment. Leukocytes may also be concentrated from the tteated stream and excess flmd eliminated This treatment may be used to treat blood borne diseases, immunological disorders and syndromes, AIDS, CFS, viral diseases, leukemtas and blood disorders. EXAMPLE 7 Fig. 6 shows a modified apparatus generally accordmg to d e system descnbed witii respect to Figs. 1-4. The system further mcludes an overheater 450, for raising the temperature of the steam above a condensation equihbnum, and a sterile solution mjector 452 with valve 453 for replacing the contaminated test solution dunng startup, wind down and dunng transients, while mamtainmg steady state operational conditions witinn die steam chamber A water cooled condensate collection chamber 454 condenses water before the vacuum pump 403 Figs 7 and 8 show results from the testing of the apparams shown in Fig 6 widi certain parameters: trace 1 is the overheated steam temperature; trace 2 is the steam temperature m generator; trace 3 is the oudet test solution temperature; trace 4 is the water temperature m steam generator; trace 5 is the heating power, W; trace 6 is the saturation pressure, kPa; trace 7 is the inlet steam pressure, kPa; trace 8 is the outlet steam pressure, kPa. EXAMPLE 8 - STERILIZATION OF INTRAVENOUS FLUIDS Intravenous fluids must be sterile on packaging and on administration. Typically, a filtration process is employed to remove all bactena in die solution. A preservative or antibiotic may also be added to die filtered solution. For sahne solutions, tins is a highly effective procedure. However, more complex solutions often clog filters and complicate the sterilization process. Further, viruses and a class of cell wall deficient bactena may pass through filters. Thus, an alternate or supplementary sterilization process may be required. In solutions having a high protem content, absorption to filter materials may represent a sigmficant loss of active matenal. Further, traditional heat sterilization (Pasteurization) is not an option due to the presence of heat-labile bioactive components. The present mvention provides a highly effective sterilization process which mamtams product potency and reduces production of degradation products. Pyrogens, bacterial cell wall components associated widi fever, must be removed from the flmd; however, a filter may be provided, for example before the atomizer, to sufficiendy remove pyrogens, without necessarily producmg a "sterile" product, free of mycoplasma, for example. The RTCP process is suitable for intravenous stock solutions and premixes, such as antibiotics, lmmunoglobuhns, peptide hormones and factors, serum and plasma, albumin, and otiier syndietic or natural components. The RTCP process provides die advantage of a non-chemical, non-denaturing process which may be used to kill typical bactenal, as well as mycoplasma (cell wall deficient bactena) and viral pathogens. EXAMPLE 9 - STERILIZATION OF PHARMACEUTICAL PRODUCTS Pharmaceutical products differ from intravenous solutions primarily m the volume and concentration of an active component. Pharmaceutical products, in particular mjectables, usually have a high concenttation of active component These differences lead to a greater mcidence of high concentration-dependent reactions between molecules of the drug, as well as precipitation of pharmaceutical product m liquids or suspensions. There are a number of mediods of sterilization now employed, but tiiese may result in toxic residues, loss or denaturation of die pharmaceutical, and may limit tiiroughput of pharmaceutical production. The process accordmg to the present mvention, may be apphed bodi dunng intermediate stages of production of pharmaceutical products, and to die final product before packaging. The intermediate stage processmg may be directed to sterilization or to other controlled effects. The final sterilization process is provided primarily to assure sterility, and may be provided in conjunction widi other complementary sterilization processes, mcludmg irradiation, chemical treatments, and filtering. EXAMPLE 10 - PROCESSING OF HUMAN MILK FOR CONSUMPTION BY NEONATES The RTCP technology is known to be effective m eliminating all or most bactena and spores from bovine milk. The use of milk treated m tins manner for human consumption is the subject of commercialization by a related entity. However, the milk of vanous species, mcludmg humans, has a number of uses besides nutrition. Human milk contains a number of substances which have been proven beneficial to mfant development. However, no technology has been available to store human milk for extended penods or at room temperature without spoilage which would not reduce some of die sigmficant benefits. In fact, to die best of our understanding, no apparams exists for convemendy sterilizing or Pasteurizing small lots of human milk. Processed milk need not be continuously refngerated, and will have a shelf hfe suitable for convemence, travel and to assist working mothers. See, Mestecky, J et al. (Eds.), Symposium on Immunology of Milk and die Neonate, Miami FL, Advances m Experimental Medicine and Biology, v. 310 (1990). Thus, the mvention may be embodies in a home human milk processmg apparams employing the RTCP process The device, for example is capable of processmg 20-200 ml of milk m a few minutes, possibly mcludmg a sterile bottling adapter. The system is preferably transparent, to allow visible gauging of cleanliness The device is also preferably portable, powered off hne current, fail-safe and self-steπ zmg The device may also be employ automatic or assisted cleaning EXAMPLE 11 - PROCESSING OF TRANSGENIC MILK Transgemc animals have been used for milk production containing transgenic products For example, a goat may produce human Antithrombm III in its milk, smtable for punfication and mjecαon A company called Genzyme Transgemcs, Framingham, MA (www.genzvme.com) is sigmficandv mvolved in tins field Pharming B V (Lieden, The Netherlands) also breeds transgemc animals for foreign protem production in milk. Typically, the transgemc product m die milk is highly punfied, so that vanous sterilization tactics may be employed. RTCP technology, because of its proven efficacy m reducmg or ehmmating bactenal contammation of milk, while avoiding denaturation of protems, may be uniquely suited for the processmg of transgemc milk in order to retain transgemc protem activity, especially dunng an earh stage of punfication. Transgemc milk may also be consumable by humans, and m tins case it is hkelv that an undenatured form of the transgemc protem would be required in die processed milk. The apparams and processmg parameters employed for processmg transgemc milk would likely be similar to those for the simple sterilization or Pasteurization of milk. EXAMPLE 12 - PROCESSING OF MILK BY-PRODUCTS Cow's milk extract ("mitogenic bovine whey extract") has been found to promote healing of wounds and ulcers Science, "Healing In Milk", 277.1045 (22 August 1997). While it is unclear which factors are important in this "naturally denved cocktail of growth factors", the RTCP technology may advantageously be employed to retain activity of peptides dunng antibactenal processmg for distribution of die whey extract as a pharmaceutical grade product. In fact, at least one company, Immunotec Research Corporation Ltd., has been granted patents (U.S. Patent Nos 5,456,924, 5,230,902 and 5,290,571) for the use of undenatured (heat labile) whey protem concentrate for the treatment of AIDS, in order to increase blood mononuclear cell glutathione concentration. EXAMPLE 13 - CELL FUSION WITH LIPOSOMES RTCP, due to die potential for controlled heating effects, has the potential to promote membrane fusion. This fusion may be symmetric between two cells or asymmetric between vesicles or hposomes and cells A hposome is an artificial structure resembling a closed sphencal cell membrane, which may be engineered to have specific membrane hpids, contents, and protems. Liposomes have been used as artificial reactors for biochemical reactors and as drug delivery systems Mossa, G , et al, "Liposomes as Bioreactors- Transport Phenomena m Proteohposomes", Biological and Syndietic Membranes, pp. 227-236, Alan R. Liss (1989); Gregonadis, G., "Liposomes as a Drug Dehver System: Optimization Studies", Gaber, B et al. (Eds.), The Technological Applications of Phosphohpid Bilayers, Vesicles and Thin Films, Plenum Press, New York (1987); Farmer, M. et al., "Liposome-Encapsulated Hemoglobm: A Syndietic Red Cell", Gaber, B. et al (Eds ), The Technological Applications of Phosphohpid Bilayers, Vesicles and Thin Films, Plenum Press, New York (1987). Red blood cells, also known as erythrocytes, are circulating blood cells which lack a nucleus. These cells have been extensively studied. Because tiiese cells are suspended in an aqueous media, tiiey have been modified for use as "microreactors", and a great body of literature has developed on die modification of erythrocytes or use of erythrocyte "ghosts" (erythrocytes with dieir contents replaced with otiier media). See, Albertini, A., et al. (eds.) Biotechnology m Clinical Medicine, Raven Press, New York (1987) , Magnani, M. et al. (eds.), The Use of Resealed Erythrocytes as Carners and Bioreactors, Plenum Press, New York (1992). Fig. 9 shows a membrane having cytochrome C, an enzyme, showing how functional systems may be created resembling cellular systems. The theory behind tins cell fusion promoting effect lies m the physics of the hpid bilayer nature of membranes. Cell membranes have a mosaic structure of vanous regions which have differing charactensttcs, mcludmg hpid composition Differing hpid compositions are, in turn, associated widi different "glass transition temperatures", analogous to a melting pomt. By raismg the temperature of a cell rapidly to a desired temperature for a short penod, portions of the membrane may become highly flmd, while other portions remain relatively intact. Thus, die cell structure is maintained. The flmd portions, on die other hand, will become weak and susceptible to otiier environmental influences, and may enter a bistable state having a non-bilayer structure. Thus, proximity of two membrane portions with at least one in tins highly flmdic condition will promote fusion, which is typically thermodynamically favorable, relieving stress on the membrane. The contents of both encapsulated spaces will merge, and the membranes will fuse. As shown m Fig. 10, tins transition, especially m experimental systems, can be quite abrupt. The Phosphohpid gel-hquid-crystalhne phase transition and die effect of cholesterol. (A) Phosphohpids, when fully hydrated, can exist in die gel, crystalline form (Lb) or m the flmd, hquid-crystalhne state (La). In bilayers of gel state PC, the molecules can be packed such diat die acyl chains are tilted widi respect to the bilayer normal (Lb state) (B) Raismg the temperature converts the crystalline state mto the hqmd crystalline phase as detected by differential scanning calonmetry. For dipalmitoyl-PC die onset of the mam transition occurs at approximately 41 °C. The pretransitton represents a small endodiermic reorganization m the packing of the gel-state hpid molecules pnor to melting. It is noted diat the changes in packing density may be associated widi volumetnc changes, causmg substantial stress when large areas of membrane change phase simultaneously. (C) Influence of cholesterol The end alpy of the phase ttansition (represented by d e area under the endotiierm) is dramatically reduced by cholesterol, which is present in die cell membranes of higher orgamsms, but absent in bacteria. At greater than 30 mol% cholesterol, the hpid phase transition seen by this techmque is effectively ehmmated. See, Davenport, L., et al., "Studies of Lipid Fluctuations Usmg polarized Fluorescence Spectroscopy", Biological and synthetic Membranes, pp. 97-106, Alan R. Liss (1989). Table 3 below shows the glass transition temperature for membranes formed of vanous compositions. TABLE 3 Temperature (Tc) and endialpy (ΔH) of die gel to quid-crystalhne phase transition of phosphohpids (m excess water) Lipid Specιes a Tc ± 2°C ΔH + 1 kcal/mol 12:0/12:0 PC b -1 3 14:0/14:0 PC 23 6 16:0/16:0 PC 41 8 1 166::00//1188::llccΔΔ 99 P PCC -5 16:lcΔ 9 /18:lcΔ 9 PC -36 9 18:0/18:0 PC 54 18:lcΔ 9 /18:lcΔ 9 PC -20 9 16:0/16:0 PE 63 9 1 166::00//1166::00 P PSS 55 9 16:0/16:0 PG 41 9 16:0/16:0 PA 67 5 a The code denotes die number of carbons per acyl chain and die number of double bonds. Δ gives the position of die double bond, c denotes as. b PC, phosphatidylchohne; PE, phosphatidyledianolamme; PS, phosphattdylsenne; PG, phosphatidylglycerol; PA, phosphattdic acid. As shown in Fig. 1 , which is a schematic drawing of a cell membrane, die membrane is normally composed of a relatively thin hpid bilayer mto which larger protem molecules may be mserted. The protems alter the microenvironment m the membrane, and dius modify die charactenstics of the surrounding portion of the membrane, allowmg local differences m properties, such as glass transition temperature, to exist. See, Edidin, M., "Molecular Motions and Membrane Organization and Function", Fmean & Mitchell (eds.) Membrane Structure, Chapter 2, Elsevier (1981); Culhs, P. et al., "Physical Properties and Functional Roles of Lipids m Membranes", Vance et al. (Eds.), Biochemistry of Lipids, Lipoproteins and Membranes, Chapter 1, Elsevier (1996); Mouπtsen, O. et al , "Protein-Lipid Interactions and hpid Heterogeneity", Watts, A. (Ed.), Protein-Lipid Interactions, Chapter 1, Elsevier (1993). Typically, hposomes are endocytosed by macrophages or rettculo-endotiie al cells, preventing fusion of die membranes. See, van Rooijen, N. et al., "Transient Suppression of Macrophage Functions by hposome-encapsulated Drugs", TIBTECH, 15:178-185 (May 1997). However, by RTCP treatment, two membranes in close proximity may be excited and made unstable ("melted") to allow fusion. The type of changes which may occur in the membranes are shown schematically m Fig. 16, along with an NMR tracing showing a change m chemical configuration. It is expected diat partial cellular permeability dunng tteatment will also be apparent, but that die cells will return to normal after RTCP tteatment. Excess RTCP tteatment, however, may result m massive loss of membrane integnty and cell deatii. The treatment need not be lethal, and in fact it is beheved diat under some condittons RTCP may selectively stimulate or activate cells. In particular, cells which have become tolerant to a condition may be subject to "rejuvenation". Since the hposome is a syndietic structure, the exact composition and charactensttcs of a hposome may be engmeered to assure efficient fusion, which occurs by a process as indicated m This process is distinct from the normal processes for clearance of hposomes from the blood. Normally, the hposomes are endocytosed or "eaten" by cells of the reticuloendodiehal system (RES), avoiding direct uptake of hposome contents and membrane fusion. This fusion may be promoted by die use of "receptors" or antibodies which specifically attract the cell surfaces together, a techmque particularly appropnate for vesicles or hposomes. These receptors may be, for example, genetically engmeered viral glycoprotems. Nonspecific absorption techmques may also be used. The fusion of a hposome with a cell may be used to alter the charactensttcs of a target cell, which may be a circulating blood cell, m vitro cell culture, biopsy cell sample, or the like. The surface of the cell is modified by die posome-bound membrane protems, while the contents of the hposome are released mto die cell. One or both of diese pnncipals may be apphed in any given case. There are, of course, other known kposome-cell fusion techmques. However, these techmques either mvolve viruses or viral protems, which may be pathogenic, toxic or antigemc, or chemicals. Therefore, the RTCP techmque has potential for a reasonably safe m vivo treatment, while other known techmques are typically limited to m vitro use. Liposomes, which have been proposed as drug delivery systems alone, are rapidly and preferentially taken up by the rettculo-endodiehal system, thus making them difficult to target to other organ systems. In contrast, normal-appearing erythrocytes are not taken up by the rettculo-endodiehal system, and may have an average circulating hfespan of 60 days. Thus, by fusing hposomes widi erythrocytes, a long lasting reservoir of drug may be obtained. It is also noted diat diere are a number of genetic diseases which are manifest as abnormalities in red blood cell protems (sickle cell anemia, thalasemia) or metabolism (glucose-6- dehydrogenase deficiency G6DH) The latter disorder is beheved to affect 400,000,000 people, and which may result m an anemia, especially m homozygous persons who mhent the defective gene from both parents, and who mgest certain foods. In die later case, for example, a genetically engmeered G6DH may be encapsulated in hposomes and die hposomes fused widi red blood cells, reversmg the deficiency and preventing the premature loss of red blood cells. Treatments would be required, for example, every 30 to 60 days. However, this technology is not limited to erythrocyte disorders. Otherwise normal erythrocytes may be targeted to a particular tissue, for example by modifying die surface structures. This surface modification may be, for example, by hposomal membrane components. The modified erythrocytes need not be returned to die venous system, and may be presented dirough the lymphatic system or other body space. By usmg erythrocytes, or even the patient's own erythrocytes, rejection and side effects are minimized. A target disease for this type of treatment is chrome viral infection, such as hepatitis (hepatitis B, hepatitis C, delta factor) or AIDS. In order to protect the normal target cells of the viral infection, red blood cells are modified to present viral receptors. Due to the large number of red blood cells, the virus load is absorbed, tending to spare the normal target cells. The red blood cells are not capable of reproducmg virus, ending the hfe cycle. A specific antiviral agent may be provided in die hposomes to further mterfere with viral reproduction (m other cells). It is noted diat tins treatment would tend to be cosdy; however, many chrome viral infections cause substantial morbidity and mortality, suggesting an advantage of even cosdy repeated treatments if efficacy is proven. EXAMPLE 14 - CELL TO CELL FUSION RTCP, due to the potential for controlled heating effects and abrupt changes in temperature, has the potential to promote cell fusion. As stated above, tins fusion may be symmetric between two cells or asymmetric between vesicles or hposomes and cells. The theory behind tins cell fusion promoting effect hes m the physics of die hpid bilayer nature of membranes. Cell membranes have a mosaic structure of vanous regions which have differing charactenstics, mcludmg hpid composition. Differing hpid compositions are, in turn, associated with different "glass transition temperatures", analogous to a melting pomt By raismg the temperature of a cell rapidly to a desired temperature for a short penod, portions of the membrane may become highly flmd, while otiier portions remain relatively intact. Thus, the cell structure is maintained. The flmd portions, on the other hand, will become weak and susceptible to otiier environmental influences, and may enter a bistable state having a non-bilayer structure. Thus, proximity of two membrane portions witii at least one in tins highly flmdic condition will promote fusion, which is typically thermodynamically favorable, relieving stress on the membrane. The contents of bodi encapsulated spaces will merge, and die membranes will fuse. Typically, the membrane structure of cells is difficult to control or modify. However, in vitro cell culture techmques mcludmg nutnent broth and mcubatton temperature, may be used to control membrane composition. While "receptors" or antibodies may be used to align cells for fusion, typically a nonspecific absorption technique might be apphed to agglomerate cells pnor to tteatment. A typical application for fused cells is the production of monoclonal antibodies. In forming a monoclonal antibody-producing cell hne, a B-lymphocyte of a selected clone (e.g., human antigen-specific) is fused witii an immortalized mouse cell hne, to produce an immortalized (continuously growing) cell hne which produces a selected type of human lmmunoglobuhn (hybπdoma). In order to produce a desired type of immunoglobuhn, hundreds or thousands of cell lines must be individually produced and tested. A more efficient fusion techmque may therefore have considerable utility. A typical use of tins techmque is the production of tumor specific antibodies as a diagnostic or therapeutic agent. In this case, the antigens on die tumor may vary between patents with the same diagnosis, so diat a large library of antibodies must be maintained or a custom production techmque implemented. The RTCP techmque may therefore be used to generate a large number of candidate clones, which may then be tested widi the actual tumor cells and dien cultured to produce sigmficant quantities, all within a clinical timeframe. In fact, the patient's own lymphocytes may be used to produce die antibodies, potentially reducmg an adverse or allergic response, and mcreasmg the possibility of finding an appropnate clone, given the existing stimulation of the patient's immune system by the tumor. EXAMPLE 15 - CELL MEDIATED IMMUNE RESPONSE VACCINE In some circumstances, antigens are more efficiendy presented by and processed from a cell surface than m soluble or precipitated form. This effect may be responsible for a number of failures of proposed vaccmes to effect long lasting immunity. RTCP-mduced cell fusion allows recombmant antigens to be presented on a desired cell type, for example erythrocytes, which may activate die body's cellular immune system to produce an effective response. Thus, a cell, such as an erythrocyte or other sacnficial cell is modified to present a foreign antigen. The antigen may be, for example, gpl20 (HIV), HBSag (Hepatitis B surface antigen), or other known antigens, not necessarily related to human disease or deficient vaccme response in humans. The antigen is provided by fusion of die sacnficial erythrocyte cell with an engmeered hposome, as discussed above Alternately, an artificial cell may be constructed by fusing one or more engmeered hposomes with a target, to produce a structure with only the desired antigemc determinants. EXAMPLE 16 - TREATMENT OF FORMED CIRCULATING BLOOD CELLS Formed cells circulating through the blood include red blood cells (erythrocytes), white blood cells (leukocytes), platelets, metastatic and abnormal cells, viremia and bacteremia. The treatment with RTCP may be used to produce a number of different effects m populations and subpopulations of d e cells These treatments mclude killing or lysis, membrane disruption (reversible or irreversible), membrane component exchange with medium, otiier cells, or vesicles or hposomes, budding of cellular components, cell fusion or hposome-cell fusion, or other effects. The RTCP technology, having millisecond temperature nse-times, disrupts or alters cell membranes and larger formed structures, while retaining protem configurations and dius avoids certain protem denaturation. For example, this RTCP techmque may be used to kill bactena or some viruses m plasma or serum. This killing may be direct, by the known diermal shock mechamsm, or by augmentation of MSP witii membrane-active compositions which reduce membrane mtegnty and d us increase cell or virus lysis under die MSP condittons. Augmentors may mclude phosphatidyledianolmmes, diacylglycerol, ethanol, short chain fatty acids, hpid peroxides, and otiier compositions. Some of diese augmentors are innocuous, may be removed or degraded, or have desired or beneficial effects. Likewise, tteatment condittons may be estabhshed which are typically non-lethal for formed cell components, vet which temporarily reduce membrane mtegnty. This temporary lapse may allow cellular contents to leach mto the extracellular flmd, allow extracellular reagents to enter the cell, or allow a reconstttution of the cell membrane with foreign protems, hpids, drugs or macromolecules. There has been much research on the use of red blood cells as a vehicle to provide a durable (approximate 60 day average hfe for a normal adult) reservoir or drug, while, depending on die particular drug, directing release mto the hver and spleen or throughout the body. Such drugs might mclude contraceptive agents, flavmoids, steroids, carotenoids, markers and radionucleides, antifungal agents (amphotenαn B), vitamin B-12, antioxidants, such as glutathione and alpha- tocopherol, and otiier compositions. The techmque also holds promise for reformulating membranes of cells, for example inserting phosphatidyl chohne or sphingomye n, cholesterol m the membrane of erythrocytes, which may reduce uptake by the reticuloendotiiehal system. Likewise, the concenttatton of tiiese compositions may be reduced to target the RES. These techmques may also be apphed to hposomes, altiiough typically the membrane composition may be defined dunng production and need not be later altered. This techmque may also offer hope for the tteatment of certain diseases m which erythrocyte membrane chemistry is abnormal, for example resulting in fragile cells and excessive hemolysis. Anodier disease which is potentially reachable by the MSP process is sickle cell anemia and vanous otiier hemoglobin abnormalities. Essentially, the erythrocytes are treated to eitiier exchange hemoglobm with a pool of normal hemoglobm (syndietic or from human or animal donors), or to access the lntracellular space of d e erythrocyte to change conditions (e.g., pH), to alter oxygen binding charactenstics. The techmque may also be used to mcrease the shelf hfe of formed blood components, such as by die addition of antioxidants to die membrane or lntracellular space, or even the introduction of enzymes necessary for vitality. The later may be effectively achieved by facilitated fusion of a cell with a hposome containing die desired membrane or cytoplasmic components. This techmque also holds promise for gene therapy, m that genetic matenal may be introduced mto cells without viral vectors. EXAMPLE 17 - SELECTIVE PROCESSING OF CELLS BY RTCP Typically, RTCP would not be expected to exert a selective effect on mammalian cells, so that a lethal tteatment for one subclass would likely be lethal for the other subclasses. Two strategies are available to mcrease selectivity of effect, resulting in differential killing or processmg. This possible selectivity is based on d e regional mosaic properties of cell membranes, vanous regions of cells have different glass transition temperatures, as well as mechamcal responses to RTCP technology. In order to gam selectivity, the entire population of cells may be subjected to a tteatment which selectively mcreases a response of a selected subgroup to the RTCP treatment, or "hardens" a selected subgroup agamst RTCP tteatment. These treatments thus seek to direcdy or indirectiy selectively alter the hpid composition of cell membranes or the effect of RTCP on die membranes. Selectivity may ensured by simple metabolic distinction, mitogemc factors, other types of selective growth factors, monoclonal antibodies, drugs or hormones. The membrane hpid changes may be effected by altenng die growth media while cell growth is selectively stimulated, fusing the selected cell populations with vesicles or hposomes of a desired composition, or employing native cellular mechanisms to alter the membrane composition. See, Horizons m Membrane Biotechnology (3 1989), Progress in Clinical and Biological Research 343. While this techmque is advantageously apphed to circulating cells in die blood, it may also be apphed to cells in culture or to cells from sohd tissues which have been suspended. The alterations possible allow cellular "reprogramming", through external engmeered additions to the cell structure. It is also conceivable to remove portions of the treated cells, such as membrane components having relatively lower transition temperatures. These cell changes may be temporary, for example the addition of exogenous receptors to cells. Thus, repeated treatments may be required to maintain a high level effect. The tteatment may employ a plasmapheresis device or mvolve removal, treatment and reinfusion of cells mto a patient. In some cases, die cells are or are made differentially sensitive to die RTCP treatment. In other cases, dunng treatment, a selective effect is apphed to a population of cells which are otherwise of equivalent sensitivity to RTCP treatment. For example, vesicles or hposomes having receptors or monoclonal antibodies are mixed widi unsorted cells and die mixture subjected to RTCP. The receptors or monoclonal antibodies mteract selectively with certain cells, having complementary cell surface structures. This is shown schematically m Fig. 18, m which the "Y" structures are specific antibodies agamst die arrow structiires on the cell surface, and the triangular structures represent a specific treatment, which readily diffuses out of a hposome, bemg provided to die cell. RTCP technology allows fusion of die hposome membrane with the cellular membrane, so that die treatment is mjected direcdy mto die cell.. The RTCP process raises the cell membranes to a temperature at which they begin to become unstable. The close proximity of the vesicles or hposomes with some cells causes a membrane fusion, which may be a physical effect or a cell mediated effect. The hposome contains either within its core or on its surface a desired treatment for the cell. This treatment may be, for example, lethal to the selected populatton, for example a cytotoxm, or membrane lytic agent, such as alpha cyclodextnn or certain cychc peptides, a free radical promoter or inhibitor (See, Proc. Int. Symp. on Free radicals in Diagnostic Medicine: A Systems Approach to Laboratory Technology, Clinical Conelattons and Anttoxidant Therapy (1993)), or a more benign treatment, such as a desired cell surface receptor system, antibiotic agent, or the like. See, Fauvelle, F. et al., "Mechamsm of a-Cyclodextnn- Induced Hemolysis. 1 The Two-Step Extraction of Phosphomositol from the Membrane", J. Pharm. Sciences, 86(8):935-943 (1997). The advantage of tins scheme is that selectivity may be mcreased, while hposome technology employed to target cells which do not normally take up hposomes. EXAMPLE 18 - IMMUNOLOGICAL AND VACCINE EFFECTS The RTCP techmque has die ability to expose normally hidden antigens from prokaryotic and eukaryotic cells, and likely from membrane-bound viruses, to the extracellular media. Thus, die techmque may find application m the production of vaccmes or autovaccination of individuals dirough the processmg of plasma m a plasmapheresis apparams. While RTCP holds tins promise, the techmque of simple exposure of antigens is the oldest of killed vaccme techmques, and m many cases is mfenor to more advanced techmques. However, where the causative agent is unknown or occult, tins techmque may allow rapid treatment with relatively safe conditions. In addition, tins techmque may also be able to address rapidly mutating species, such as HIV variants and cancer cells, by exposing the actual antigens present, rather those of an exemplar. While raw disrupted cellular matenal has been used m die past as die basis to establish an immune response, this is considered mfenor to a vaccme engmeered to develop a specific immune response to an identified component of die cell, to which an immune response results m useful activation of die body's immune system. It should be understood diat die preferred embodiments and examples descnbed herem are for illustrative purposes only and are not to be construed as limiting die scope of die present mvention, which is properly delineated only m die appended claims.

Claims: CLAIMS What is claimed is. 1. A mediod for processmg a hpid membrane bound structure, compnsmg the steps of providing the structure to be processed m a hqmd medium; and heating die hqmd medium containmg die structure at a rate and dirough a temperature range sufficient to cause an instability in die structure without lysing the structure. 2. The method accordmg to claim 1, wherem the membrane-bound structure compπses a hpid bilayer 3. The method according to claim 1, wherem the structure is a hposome. 4 The mediod accordmg to claim 1 , wherem the structure is a vesicle. 5 The method accordmg to claim 1 , wherem the structure is a prokaryottc cell. 6. The mediod accordmg to claim 1, wherem the structure is a eukaryotic cell. 7. The method accordmg to claim 1, wherem the structure to be processed is a living cell, and die instability contributes to cell membrane fusion. 8 The method accordmg to claim 1 , wherem the structure to be processed is a cell, and die instability alters a tactic response of the cell. 9 The method accordmg to claim 1 , wherem the hqmd contains a second type of membrane-bound structure. 10. The method accordmg to claim 9, wherem the second type of structure is a cell, and die instability promotes fusion of the structure and die cell. 1 The method according to claim 10, wherem the fusion product of die structure and cell remains ahve. 12. The method accordmg to claim 9, wherem the structure is a hposome and die second type of structure is a cell. 13. The method accordmg to claim 12, wherem the hposome fuses with the cell. 14. The method according to claim 9, wherem the structure is an engmeered structure and die second type of structure is a cell, the engmeered structure havmg an effective glass transition temperature below an average glass transition temperature of the cell. 15. The method accordmg to claim 1, wherem the structure is heated at a rate and through a range sufficient to cause a discrete ttansitton m at least one portion of die membrane of the structure. 16. The method accordmg to claim 1 , wherem the structure is heated at a rate and dirough a range sufficient to generate a shock wave m the membrane to reduce an mtegnty diereof 17. The method accordmg to claim 1, wherem the structure is heated at a rate sufficient and dirough a range appropnate to cause an abrupt glass ttansitton m a portion of die membrane. 18. The method accordmg to claim 1 , wherem at least a portion of the membrane undergoes a gel to hqmd state ttansition. 19. The method accordmg to claim 1, wherem the temperature nse rate exceeds an accommodation rate of at least a portion of the membrane. 20. The mediod accordmg to claim 1 , wherem at least a portion of the membrane changes from a bilayer state to a non-bilayer state. 21. The method accordmg to claim 1, wherein said heating causes a non-hnear change m packing density of molecules forming the membrane. 22. The method accordmg to claim 1 , wherem the structure is a formed blood component. 23. The method according to claim 22, wherem the structure is an erythrocyte. 24. The method accordmg to claim 22, wherem the structure is a lymphocyte. 25. The method accordmg to claim 1 , wherein the structure is suspended m blood plasma. 26. The method accordmg to claim 1, wherem the structure is an abnormal cell. 27. The method according to claim 1, wherem the structure is a differentiated cell havmg a specific defined secretory gene product. 28. The method according to claim 1, wherem the structure contains a drug. 29. The method accordmg to claim 1, wherem the structure contains a superphysiological concenttatton of a single enzyme. 30. The method accordmg to claim 1, wherem the structure compnses a composition which mteracts with a cellular receptor. 31. The method accordmg to claim 1, wherem the structure compnses a composition which regulates gene product expression. 32. The method accordmg to claim 1, wherem the structure compnses a protease inhibitor. 33. The method accordmg to claim 1 , further compnsmg die step of inserting the processed structure mto a multicellular orgamsm. 34. The method accordmg to claim 33, wherem the processed structure is mserted mto die circulatory system of a mammal. 35 The method according to claim 33, wherem the processed structure is mserted mto die lymphatic system of a mammal. 36. The mediod accordmg to claim 1, further compnsmg the step of applying an ionizing radiation treatment to the structure 37. The method accordmg to claim 1, further compnsmg the step of subjecting die structure to an oxidizing agent. 38 The method accordmg to claim 1 , further compnsmg the step of subjecting die structure to non-ionizing radiation. 39 The mediod accordmg to claim 1, wherem the heating temperature nse rate exceeds 100 C per second. 40. The method accordmg to claim 1, wherem the heating temperature nse rate exceeds 1000 C per second. 41. The method accordmg to claim 1, wherem the heating temperature nse is less than 40 C. 42. The method accordmg to claim 1, wherem the heating temperature nse is greater than 10 C. 43. The method accordmg to claim 1, wherem a maximum heating temperature is less than about 55 C. 44. The method accordmg to claim 1, wherem a maximum heating temperature is less than about 43 C. 45. The method according to claim 1, wherem said heating does not substantially denature protems of the structure. 46. The method accordmg to claim 1 , wherem said instability exposes normally hidden antigens. 47. The method accordmg to claim 1, wherem said heating is effected dirough contact of die medium widi steam. 48. The method accordmg to claim 1, wherem the medium is atomized pnor to heating. 49. The method accordmg to claim 48, wherem the atomized medium is heated while moving at a velocity of at least about 100 cm/sec. 50. The mediod accordmg to claim 1, wherem the medium is subject to mechamcal forces synchronized with and mdependent of said heating. 51. The mediod accordmg to claim 1, wherem an amount of medium between about 1- 50 ml per minute. 52. The method accordmg to claim 1, wherem the structure has a viral receptor protem on its outer surface 53. The method according to claim 1, wherem said structure contains nucleic acid encoding at least one gene or regulator. 54. The method accordmg to claim 1 , wherem the structure is a cell, further compnsmg the step of incubating die cell under such conditions as to alter a cell membrane hpid composition. 55. The method accordmg to claim 1 , wherem the structure is fused as a result of the mstabihty to produce a monclonal antibody producmg chimenc hybndoma. 56. The method accordmg to claim 1, wherem the structure has an antigemc composition on an outer surface thereof 57 The method accordmg to claim 1 , wherem structures of at least three types are subjected to treatment simultaneously, to cause a fusion of die diree structures. 58. The method accordmg to claim 1, wherem the medium contains one or more fusion augmenting agents selected from the group consisting of phosphatidyletiianolmines, diacylglycerol, ethanol, short chain fatty acids, and hpid peroxides. 59. The mediod accordmg to claim 1, wherem the structure contain a cytotoxic agent. 60. A method for processmg a medium containing two types of hpid membrane bound structures, compnsmg the steps of providing the structures to be processed m a hqmd medium; and heating die hqmd medium containing die structures at a rate and dirough a temperature range sufficient to cause an mstabihty m at least a portion of the membrane of one of the structiires without lysmg the other structure. 61. A method for processmg mammalian milk containmg bactenal contaminants, compnsmg the steps of heating the milk at a rate and dirough a temperamre range sufficient to kill bactena substantially without denatunng protems m the milk; and selectively punfymg protems in die milk. 63. The method accordmg to claim 62, wherem the milk is denved from a transgemc animal. 64. The mediod accordmg to claim 62, wherem the milk contains human protems. 65. The method according to claim 62, further compnsmg die step of preparing the selectively purified protem as a pharmaceutical preparation. 66. A method for processmg a hpid membrane bound structure, compnsmg the steps of heatmg die structure at a rate and through a temperamre range sufficient to cause an mstabihty m at least a portion of the hpid membrane, resulting m a temporary alteration of a membrane mtegnty of the structure. 67. A method for processmg a medium containmg hpid membrane bound structures, compnsmg the steps of providing the structures to be processed m a hqmd medium; and heating die hqmd medium containing the structures at a rate and dirough a temperature range sufficient to cause an mstabihty m at least a portion of the membrane of one of the structures and diereby causing a membrane fusion of die two structures. 68. A method for processmg a medium containmg hpid membrane bound structures having protems associated dierewith, compnsmg the steps of providing die structures to be processed m a hqmd medium; and heating die hqmd medium containing die structures at a rate and dirough a temperature range sufficient to cause an mstabihty m at least a portion of the membrane of the structures, thereby causmg an interaction between the structures without denatunng associated protems. 69. An apparams for processmg a medium containing hpid membrane bound structures havmg protems associated therewith, for heating the hqmd medium containmg the structures at a rate and through a temperature range sufficient to cause an mstabihty m at least a portion of the membrane of the structures, diereby causmg an interaction between the structures without denatunng associated protems, compnsmg means for ensuring a low average density stream of medium containmg die hpid membrane bound structures and associated protems and means for heating die low average density stream of medium witinn ttghdy controlled temperature profile parameters. 70. The apparams accordmg to claim 69, wherem the apparams operates m a steady state condition for an extended penod. 71. The method accordmg to claim 1, wherem said heating is effected dirough contact of the medium widi steam supplied at a temperature above an equihbnum condensation temperature. 72. The method accordmg to claim 1, wherem said heating is effected by contact of the medium widi superheated steam.

Inventors: GRAE JOEL B, GRAE, JOEL, B.
Applicants: GRAE JOEL B, IB2 L L C, GRAE, JOEL, B., IB2, L.L.C.
Application year: 1998
Main classification: C12N13
IPC codes: C12N13, C12N15